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Cancer is a heterogeneous group of diseases that currently takes over half a million lives 
per year in the United States alone. Our understanding of cancer has improved dramatically over 
the last forty years, beginning with the discovery that cancer is a disease of the genome. 
Currently, the set of somatic mutations found in malignancy are largely known. The specific 
somatic mutations driving an individual’s disease can be readily assessed at clinical presentation. 
Additionally, the functional consequences for many of these mutations are known as well as their 
role in tumorigenesis. Despite this understanding, a cure for cancer remains elusive. 
Acute myeloid leukemia (AML) is a particularly deadly example, which currently kills 
about 10,000 people per year and has a 5-year survival rate of only 25%. While the current 
outlook for these patients is grim, much is known about the disease, which will fuel future 
improvements in detection and therapy. Existing research has identified the spectrum of somatic 
mutations driving most cases of AML and has elucidated the oligoclonal nature of the disease. 
Following treatment, relapse often arises from a minor clone that was inconspicuous at 
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presentation, but resistant to treatment. The current gold standard for assessing response to 
treatment is multiparameter flow cytometry (MPFC), which identifies persistent leukemic cells 
marked by a patient-specific leukemia-associated immunophenotype. Unfortunately, MPFC is 
only useful in a subset of patients and not sensitive to the clonal diversity present in many 
tumors. Conversely, virtually every case of AML is marked by leukemia-specific somatic 
mutations that theoretically distinguish every leukemic cell from its normal counterparts.  
These limitations of MPFC and the general need for improved residual disease detection 
were early motivations for this thesis work: to develop a sequencing-based modality for rare 
leukemic-clone detection. Previous efforts to develop a sequencing-based platform for residual 
disease detection had largely failed because of the intrinsic error rate of next-generation 
sequencing (NGS) technology, which precludes the detection of leukemic clones less common 
than 1:20 cells (0.025 variant allele fraction for heterozygous mutations). For comparison, MPFC 
is sensitive and prognostic to a detection limit of 1:10,000 cells. To address this limitation, we 
developed methods for targeted error-corrected sequencing that mitigated the effect of 
sequencing errors. After an extensive development and validation process, we applied this 
technology to study two fundamental questions in AML and hematopoiesis in general.  
First, we applied our error-corrected sequencing methods to study leukemogenesis in 
therapy-related AML (t-AML). This aggressive form of leukemia arises months to years 
following treatment with chemotherapy or radiation for a primary malignancy. The prevailing 
notion was that antecedent therapy introduced somatic mutations in hematopoietic stem and 
progenitor cells (HSPCs) that directly caused the development of t-AML. We used error-
corrected sequencing to demonstrate that leukemogenic TP53 mutations were present at low 
frequency months to years before the diagnosis of t-AML and in some cases preceded the initial 
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chemotherapy exposure. These findings redefined the etiology of t-AML. Instead of being 
introduced by chemotherapy, these TP53 mutations likely arose stochastically in HSPCs 
throughout the patient’s lifetime and were selected for by cytotoxic therapy, eventually spawning 
malignancy. 
Second, we applied error-corrected sequencing to further our understanding of benign 
clonal hematopoiesis in healthy individuals over time. Recent work had identified benign 
hematopoietic clones harboring leukemia-specific somatic mutations in the blood of healthy 
individuals. The prevalence of this phenomenon increased as a function of age; while rare below 
50, clones were detected in up to 10% of individuals by 70 years-old. These findings were made 
with conventional NGS and, likewise, did not detect rare clonal mutations in fewer than 1:20 
cells. We sought to characterize the prevalence, stability and mutation spectrum of benign 
hematopoietic clones below this threshold. Using our error-corrected sequencing approach, we 
demonstrated that approximately 95% of disease-free individuals have hematopoietic clones 
harboring leukemia-associated mutations by 50-60 years of age. We also demonstrated that these 
clonal mutations were stable over time and originated in long-lived HSPCs. 
These findings demonstrate the utility of our error-corrected sequencing platform to 
identify and characterize previously undetectable leukemia-associated somatic mutations. We 
applied these techniques to unveiled new insights into clonal HSPC biology and the development 
of t-AML. Future work will apply this technology as a sequencing-based modality for residual 
disease detection in pediatric AML. We believe this technology will improve the detection of 
residual leukemia, identify the step-by-step molecular perturbations driving relapse, inform 
therapeutic selection, and improve clinical outcomes and survival.  
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Chapter 1: Introduction 
1.1 Cancer is a Genetic Disease 
Cancer is the second most common cause of death in the United States, predicted to take 
over half a million lives in 20161. History has demonstrated that effective treatment of this 
heterogeneous disease requires a thorough understanding of the molecular alterations that drive 
each individual’s malignancy2. Forty years ago it was postulated by Peter Nowell that cancer is 
an evolutionary process by which normal cells sequentially acquire somatic mutations, 
experience drift and are selected for by the environment3. This theory built upon the 
groundbreaking discoveries by Janet Rowley, who first characterized the t(8;21)(q22;q22) 
RUNX1/RUNX1T1 translocation found in 5% of acute myeloid leukemia (AML) cases, the 
universal Philadelphia chromosome t(9;22)(q34;q11) BCR/ABL translocation found in chronic 
myeloid leukemia (CML), and the canonical t(15;17)(q24.1;q21) PML/RARA translocation found 
in acute promyelocytic leukemia4–7. Additional contemporary work characterized X-inactivation 
skewing in tumor samples from female patients, which characterized the monoclonal (CML, 
Burkitt’s lymphoma, polycythemia vera, myelofibrosis) or polyclonal (hereditary neurofibromas) 
origin of several neoplasms8–13. Interestingly, while neurofibromas had a polyclonal origin, 
malignant transformation into a neurofibrosarcoma arose from a single cell14. These findings 
definitively demonstrated that cancer is a genetic disease, likely originating from a single cell, 
and founded the field of cancer genetics15. These concepts were further bolstered by studies 
examining clonal evolution and heterogeneity at the chromosomal level via karyotype 
analysis16,17. This was followed by the seminal discovery of the first cancer-causing DNA 
sequence change—a guanine to thymine substitution in codon 12 of HRAS18,19. This discovery 
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utilized Maxam-Gilbert sequencing—a newly developed technique for quickly reading the 
nucleotide sequence of short DNA fragments20. This technology and another concurrently 
developed sequencing technology—Sanger sequencing—were the primary workhorses for 
cancer sequencing studies over the next 20 years and launched a new era of cancer genomics21.  
1.2 The Human Genome Project, Sequencing Cancer 
Genomes, A Catalog of Cancer Associated Genes 
Shortly after the turn of the 21st century, completing the first reference human genome 
sequence provided a framework to map the evolutionary process of tumorigenesis at the level of 
individual nucleotides22,23. Focusing on malignancy, early exome-sequencing studies leveraged 
this reference genome to provide the first characterization of mutations in breast and colorectal 
cancer24,25. These herculean efforts sequenced hundreds of thousands of PCR amplicons to 
discover thousands of germline and somatic mutations present in the tumor samples. These 
studies highlighted the necessity of comparing the sequencing results from individually matched 
tumor and normal samples in order to distinguish somatic mutations from constitutional variants 
that differed from the reference genome sequence. Through targeted sequencing of candidate 
gene panels, other large collaborative sequencing studies identified a spectrum of somatic 
mutations in multiple types of malignancies including glioblastoma, colorectal cancer, 
adenocarcinoma, renal carcinoma, myeloproliferative neoplasms and pancreatic cancer26–32. 
Together these observations elucidated the vast heterogeneity of somatic mutation burden and 
substitution types between different tumor types that resulted from the specific environmental 
exposures, such as UV light in melanoma, carcinogen exposure in lung cancer and DNA damage 
repair defects33,34. During this period, each new discovery expanded the list of specific genetic 
alterations that caused cancer, estimating that only a few hundred out of the 20,000-25,000 
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protein-coding genes in the human genome routinely contribute to malignant transformation35,36. 
Today, these lists of curated cancer-associated genes and detected somatic mutations are 
maintained at the Cancer Gene Census and Catalogue of Somatic Mutations in Cancer 
(COSMIC), respectively35,37,38. 
The subsequent development of massively parallel sequencing—also known as next-
generation sequencing (NGS) or second-generation sequencing—reduced costs by two orders of 
magnitude and moved nucleic acid sequencing out of the a global network of large production 
facilities that generated the first human reference genome and into smaller research labs studying 
the panoply of biological processes and diseases39–42. This technology enabled the first matched 
tumor/normal whole genome sequencing (WGS) study, which characterized the spectrum of 
somatic single nucleotide substitutions and small insertion/deletion (indel) mutations within a 
single case of normal karyotype adult de novo AML43. Surprisingly, this study identified only 10 
coding somatic mutations, again, highlighting the importance of a matched normal sample to 
filter out inherited constitutional variants43. A subsequent study of another normal karyotype 
AML case revealed only 12 coding somatic mutations including the hot spot IDH1 R132C 
mutation, which was subsequently identified in several other AML cases44. Reanalysis of the 
first AML case to undergo WGS identified a frameshift mutation in DNMT3A—a DNA 
methyltransferase that catalyzes the de novo methylation of cytosine in CpG dinucleotides45. 
Abnormal DNA methylation leading to epigenetic dysregulation was hypothesized to contribute 
to the development of cancer46. This finding led to the characterization of recurrent mutations in 
DNMT3A (present in one-third of normal karyotype AML cases) and hotspot mutations affecting 
the arginine 882 amino acid (present in almost two thirds of DNMT3A mutations in AML)45. A 
similar German study characterized the spectrum and prevalence of IDH1 and IDH2 mutations 
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(found in the second AML WGS study) identifying IDH1 or IDH2 mutations in 16% of adults 
with AML47. These studies highlight the power of unbiased WGS studies to uncover potent 
drivers of malignancy and subsequently quantify the prevalence of those mutations and outcomes 
in affected individuals.  
These early studies opened the floodgates for the unbiased detection of somatic mutations 
in any and all forms of malignancy. Subsequent studies characterized the spectrum of somatic 
mutations in multiple malignancies including breast cancer, malignant melanoma, and small-cell 
lung cancer48–52. These studies provided the first broad characterization of “cancer genome 
landscapes,” specifically identifying the few genes that harbor somatic mutations in a wide 
variety of malignancies and the many genes that are less frequently mutated53. A comprehensive 
review from Bert Vogelstein et al. summarized the following observations: 1) the number of 
non-synonymous mutations per cancer type was highly variable with up to 1000 in colorectal 
cancer with microsatellite instability, 100-200 in lung cancer and melanoma (due to 
environmental mutagen exposure), and approximately 10 in liquid tumors (e.g. AML and CML) 
and pediatric cancers (e.g. glioblastoma, neuroblastoma and medulloblastoma); 2) a typical 
tumor only contained 2-8 “driver” mutations and the rest were inconsequential passenger 
mutations that arose throughout the natural history of the cell that founded the malignancy; 3) 
tumors were almost universally heterogeneous, which would impact response to treatment53. 
Subsequently, the Cancer Genome Atlas’ analysis of 3,281 tumors across 12 cancer types and 
The Broad Institute’s analysis of 4,742 tumors across 21 cancer types cemented these concepts, 
producing a comprehensive catalog of cancer associated genes54,55. In AML the genomic 
landscape of somatic mutations was further refined by leukemia/normal WGS or whole exome 
sequencing (WES) for 200 cases of AML56. The overwhelming amount of data generated by 
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these studies required the development of new tools to distinguish putative driver mutations from 
the bevy of passenger mutations that were also detected57. These discoveries established the 
foundation necessary to realize the goal of personalized medicine, where each patient’s cancer 
will be genotyped accurately at diagnosis, the cancer-specific pathways and susceptibilities will 
be identified, and a personalized therapeutic plan will be initialized58. However, as our 
understanding of the cancer genome has progressed, so has our understanding of clonal 
heterogeneity and evolution, curtailing early hopes for an easily produced, genomically forged 
cure for cancer. 
1.3 Clonal Heterogeneity and Clonal Evolution 
With an accurate reference set of cancer associated genes and mutations, the next 
important step in understanding the genomic basis of malignancy was to describe the 
heterogeneity within a single individual’s malignancy and the clonal evolution of that 
malignancy over time. Heterogeneity within an individual’s tumor was first observed long ago 
using karyotype analysis17,59. However, NGS made it possible to characterize this heterogeneity 
throughout the genome. One elegant study sequenced multiple sections from a single pancreas 
inundated with carcinoma along with several distant metastases to clearly show that genomic 
heterogeneity increased geographically across the primary lesion. Additionally, peritoneal 
metastases were similar to the primary tumor, and the liver and lung metastases were drastically 
different from the primary tumor60. Another study described likely convergent evolution within a 
single case of renal cell carcinoma in which three different, geographically separated somatic 
mutations in SETD2 were identified in a tumor already missing the other copy of SETD2 because 
of a ubiquitous chromosome 3p deletion61. These initial studies demonstrated the geographic 
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heterogeneity found within solid malignancies and provide some insights into the mechanisms 
for metastasizing, treatment resistance and recurrence.  
Focusing on liquid tumors, while a rare group of diseases overall, there are several key 
advantages regarding the study of clonal evolution that are worth noting. For liquid tumors, 
samples are often serially banked over the disease course of a single individual, samples are 
relatively free of contaminating normal tissue, phenotypically identical cells are easily sorted for 
analysis of specific subpopulations of cells, and comparable healthy tissue is easily obtained. 
These features enable the in-depth study of clonal heterogeneity within an individual’s disease. 
The clonal structure of AML was elegantly described by John Welch et al. in a study utilizing 
WGS to characterize the somatic mutations present in 12 cases of French-American-British 
(FAB) classified M3 AML (each containing the canonical PML-RAR translocation) and 12 
cases of M1 AML with an unknown initiating lesion62. This study presented several interesting 
findings: 1) most somatic mutations found in AML were benign events that occur during the 
natural history of the initiating cell before leukemic transformation; 2) the AML samples were 
almost universally oligoclonal with multiple clones present at diagnosis; and 3) the founding 
clone in M1 AML frequently had mutations in DNMT3A, IDH1, TET2 or NPM162. Another 
important study described the clonal architecture of secondary AML (sAML)—AML that arises 
from antecedent myelodysplastic syndrome (MDS) in the setting of ineffective hematopoiesis63. 
This study observed that clonal hematopoiesis in the bone marrow was indistinguishable between 
MDS and sAML, all of the sAML samples were oligoclonal (2-5 clones detected per person), 
and sAML arose from persistent MDS clones that acquired additional functional mutations. 
While these were both groundbreaking studies, it is humbling to think that these observations 
were predicted by Peter Nowell, Janet Rowley and others nearly 40 years earlier. Interestingly, 
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the Welch et al. study demonstrated that AML arose in cells with a somatic mutation burden 
similar to healthy age-matched hematopoietic stem and progenitor cells (HSPCs), suggesting that 
AML could arise without an elevated intrinsic mutation rate required for other cell types to 
undergo malignant transformation58,62.  
The effect of therapy on the clonal characteristics of AML were demonstrated by studies 
of relapsed AML. The clonal evolution of relapsed AML was described in a WGS study of eight 
cases of AML at diagnosis and relapse, which found that relapse clones could either arise 
directly from the primary leukemia (three cases) or arise from a subclone that survived the initial 
treatment (five cases)64. The vast majority of somatic mutations detected were shared between 
the primary sample and the relapsed sample, again demonstrating that most somatic mutations in 
AML arose prior to leukemic transformation. Additionally, these cases frequently acquired 
additional mutations at relapse (even if recurring directly from the primary leukemia). This 
reiterates the challenge of effectively treating this disease, which necessitates the eradication of 
the primary tumor and all subclones that could seed relapse. A subsequent study of clonal 
evolution in NPM1-mutated AML observed that at relapse DNMT3A mutations co-occurring at 
diagnosis were almost universally retained, but NPM1 mutations were occasionally lost, 
suggesting that DNMT3A mutations might have occurred earlier in the founding clone than the 
NPM1 mutations65. Another interesting case report described the clonal evolution of a single 
IDH1 R132L-mutated AML, which acquired a canonical spliceosome SF3B1 K700E mutation at 
relapse 19 years later66. Similar findings were also described in acute lymphoblastic leukemia 
(ALL), chronic lymphocytic leukemia (CLL), CML and multiple myeloma67–74. These are just a 
handful of the studies that demonstrated the dynamics of clonal complexity in liquid tumors that 
have relapsed following treatment.  
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The recent development of single-cell sequencing technology has enabled further study 
of clonal heterogeneity in malignancy. The earliest forms of this technology were applied to 
solid malignancies to enable the separation of malignant cells from adjacent non-malignant 
stroma. An early single-cell sequencing approach utilized whole-genome amplification of flow 
sorted nuclei and low coverage sequencing to assess clonal diversity at the level of copy-number 
changes, demonstrating a large phylogenetic separation between a primary breast tumor and 
hepatic metastases75. Another early study used single-cell whole exome sequencing to describe 
the clonal architecture of clear cell renal carcinoma76. Surprisingly, while the normal cells 
clustered tightly together, the malignant cells did not, suggesting that clear cell renal carcinoma 
may be more clonally diverse than expected76. A concurrent study reported the monoclonal 
origin of a single case of JAK2-negative essential thrombocythemia77. While this technology has 
matured in recent years there are still many associated technical challenges such as single cell 
isolation, unbiased amplification of genomic DNA and sequence data analysis78. The single-cell 
analysis of liquid tumors is somewhat easier, but still developing. One of the largest single cell 
studies to date analyzed approximately 800 cells from 6 pediatric ALL patients using targeted 
resequencing of mutations identified in their bulk tumors79. Despite a high level of allelic 
dropout, the investigators were able to accurately describe the clonal architecture of each 
individual’s disease and the hierarchy of clonal mutations. Surprisingly, they demonstrated that 
mutations present at similar variant allele fractions (VAFs) often occurred in separate clones of 
similar size. In a separate study, the single-cell analysis of three individuals with sAML refined 
the clonal hierarchy predicted by prior bulk sequencing, which enabled the accurate clustering of 
variants that were outliers in the bulk sequencing analysis63,80. Another contemporary study 
examined the functional consequences of clonal heterogeneity in AML and discovered that most 
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clones circulate in the peripheral blood, subclonal mutations appeared in non-leukemic normal 
hematopoietic compartments, and engraftment potential in xenograft models varied drastically 
and unpredictably between subclones81. This study also used single-cell sequencing to verify the 
clonal hierarchy predicted by bulk sequencing. Even when a single participant of this study, 
AML31, was re-sequenced at 10-fold greater coverage (yielding 11-fold more “platinum” variant 
calls) in a follow-up study, the clonal hierarchy was still informed by the previous single-cell 
sequencing results81,82. Additionally, this ultra-deep sequencing study demonstrated that clonal 
diversity was much more complicated than previously thought; standard WGS identifying 3 
clones at diagnosis and one at relapse compared to deep sequencing which identified 1 founding 
clone, 3 subclones in the primary tumor, 1 separate clone enriched from diagnosis to relapse, and 
at least 1 clone gained in relapse64,82. These studies have expanded our understanding of clonal 
dynamics and heterogeneity in AML. As the technology improves, the vast complexity of AML, 
and malignancy in general, is slowly being unveiled.  
1.4 Pre-Leukemic Hematopoietic Stem Cells 
The studies mentioned previously also supported the growing understanding of pre-
leukemic HSPCs, which carry several of the activating mutations necessary for leukemic 
transformation, but still maintain ostensibly normal hematopoiesis. Early evidence from this 
theory came from the observation of RUNX1-RUNX1T1 (AML-ETO) t(8;21)(q22;q22) 
translocation in normal-appearing long-term remission samples from individuals treated for 
AML83. They observed expression of the RUNX1-RUNX1T1 translocation in healthy 
hematopoietic stem cells (HSCs), monocytes and B lymphocytes, suggesting that HSCs with the 
translocation were capable of self-renewal and differentiation into mature blood cells. In another 
case, pre-leukemic HSCs were detected in two year-old twins discordant for ALL containing the 
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ETV6-RUNX1 t(12;21)(p13;q22) translocation84. An early application of genomics to this field 
utilized exome sequencing to identify somatic mutations in six cases of AML (3-19 per person) 
and then examined the prevalence of these mutations in non-leukemic HSCs85. Non-leukemic 
HSCs were isolated by fluorescence activated cell sorting (FACS) and functionally validated by 
xenograft transplant into immunodeficient mice. In five out of six cases they identified some, but 
not all, of the leukemia-associated mutations in these HSCs that preceded the AML clone. Using 
single-cell colony formation and genotyping, the researchers temporally ordered the sequence of 
mutation acquisition from non-leukemic HSCs containing different subsets of the leukemia-
associated mutations. Follow-up work from the same group examined the clonal evolution of 
these pre-leukemic HSCs and how they respond to induction chemotherapy86. Interestingly, they 
observed that mutations affecting epigenetic regulation (DNA methylation, histone modification 
and chromatin looping) occurred early in the development of disease and mutations conferring a 
proliferative advantage occurred late. Using single-cell genotyping, they elegantly and 
convincingly demonstrated the multistep process of mutation acquisition within individual HSCs 
that contain increasing subsets of the somatic mutations present in the leukemic sample. 
Furthermore, this work demonstrated that pre-leukemic HSCs harboring early driver mutations 
survive induction chemotherapy and may be an important cause of relapse. A concurrent study 
made similar observations in cases of DNMT3A and NPM1 mutated AML, where pre-leukemic 
HSCs with only the DNMT3A mutation survived chemotherapy treatment and were capable of 
multilineage engraftment in mice87. More recent studies reported persistent DNMT3A R882 and 
IDH2 R140Q mutations in long-term remission following treatment for AML88,89. These findings 
supported the theory that the somatic mutations in AML arise through the sequential acquisition 
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of (largely non-functional) mutations in self-renewing HSCs and that pre-leukemic HSCs exist at 
diagnosis that harbor some, but not all, of the mutations present in the founding AML clone.  
1.5 Residual Disease Detection 
At the beginning of this thesis work, virtually all of the driver mutations in AML had 
been uncovered, the clonal structure and temporal evolution of several AML cases had been 
described, and there was growing evidence that pre-leukemic HSCs harboring a subset of the 
AML-associated somatic mutations survived chemotherapy and could spawn relapse. The 
genomic tools and understanding were in place to develop a sequencing-based modality for 
residual disease detection in AML. Specifically, following induction therapy, could persistent 
leukemia-associated mutations in peripheral blood or bone marrow samples predict relapse and 
overall survival? While initially unsuccessful, we made several advancements in the detection of 
rare hematopoietic clonal mutations that will hopefully be useful in the future realization of this 
goal.   
The current gold standard for assessing residual disease following treatment for AML is 
multiparameter flow cytometry (MPFC)90. Leukemic cells are identified by a leukemia-
associated immunophenotype (LAIP) that is not present on normal hematopoietic cells. These 
differences can manifest as different expression levels of normal cell surface markers, 
abnormalities in timing of marker expression given the normal differentiation program or the co-
occurrence of markers not normally present on the same cell90,91. In pediatric AML, detecting 
any residual disease by MPFC (using a different-from-normal approach) at the end of induction 
(1 or 2) or end of therapy was associated with an increased risk of relapse and shorter relapse 
free survival92. In a separate study of pediatric AML, detecting residual disease above 1 leukemic 
cell in 1,000 mononuclear bone-marrow cells by MPFC (using a LAIP approach) was also 
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associated with an increased risk of relapse and shorter relapse free survival93. These results 
extended to young adults (<60 years old) and older adults (>=60 years old) treated for AML94,95. 
While most studies simply reported presence or absence of an LAIP during assessment, one 
study suggested that a detection cutoff of 0.15% maximized the receiver operator characteristics 
for predicting relapse96. However, other groups advocated for a more sensitive cutoff for positive 
residual disease of 0.035% residual leukemic cells in the bone marrow97. This variability 
between study designs reflects a broader lack of standardization in the field that hinders large-
scale application and prevents comparison of results from different studies98,99. Another 
alternative method for residual disease detection is quantitative PCR (qPCR), which targets 
leukemia-associated translocations. This method is sensitive to detect residual leukemic cells 
present at 1:10,000-1:1,000,000 cells, about two orders of magnitude lower that MPFC100. 
However, it is only suitable in the 15-60% of AML patients with a canonical translocation or a 
suitable NPM1 frameshift mutation for which PCR primers have already been designed98,101. 
Despite these limitations, both methods have been used successfully to stratify patient outcomes 
based on detecting residual leukemic cells following treatment.  
Even with these findings, there was mounting evidence that the LAIP identified at 
diagnosis frequently changed by relapse (up to 91% of AML cases)102. Additionally, 
heterogeneity in the primary AML tumor made the detection of residual or relapsed disease 
originating from previously uncharacterized subclones more challenging103. In B-ALL this was 
an especially dire problem as treatment often directly targeted CD19, the antigen primarily used 
for detection, such that relapse clones often lacked the CD19 antigen104. These are phenotypic 
manifestations of the underlying genomic clonal evolution and selection richly characterized by 
the aforementioned sequencing studies that nonetheless limits the efficacy of MPFC for detecting 
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recurrent disease. Conversely, virtually all cases of AML have somatic mutations that uniquely 
mark the primary tumor, subclones or the pre-leukemic clone that will seed relapse. In broad 
strokes, sequencing could determine the spectrum of somatic mutations in the primary tumor and 
predominant subclones at diagnosis to inform targeted treatment selection and sequencing-based 
residual disease detection. While useful for tracking, knowing the spectrum of somatic mutations 
at diagnosis would not be essential for residual disease detection. By querying all of the 
recurrently mutated genes in AML, the assay would detect relapsing clones with or without the 
somatic mutations identified at diagnosis. Early applications of NGS for residual disease 
detection focused on simply detecting indels in recurrently mutated loci that were easy to capture 
by PCR amplification for sequencing. One report demonstrated that FLT3 internal tandem 
duplications (15-300 bp long) could be reliably captured from genomic DNA, sequenced with 
short paired-end NGS (101 bp paired-end reads), and aligned/assembled using a combination of 
bioinformatics tools to identify the  samples with the mutation105. Subsequent studies could also 
assess somatic single nucleotide variants for residual disease detection. One early example in T-
lineage acute lymphoblastic leukemia/lymphoma demonstrated that sequencing the T-cell 
receptor—which is a unique clonal marker for disease—at post-treatment day 29 was much more 
sensitive than MPFC for detecting residual disease106. Similar results were observed by the same 
group when sequencing the immunoglobulin heavy chain locus in cases of B lymphoblastic 
leukemia107. Interestingly, in both studies, MPFC failed to detect residual disease in several cases 
where sequencing identified residual disease in greater than 1:1,000 cells, well above the usual 
limit of detection for MPFC106,107. In AML, residual disease was reliably detected in studies 
specifically sequencing NPM1, RUNX1, and FLT3-ITD and often detected in cases originally 
deemed negative by MPFC108–110. In the RUNX1 study, the frequency of detected residual 
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RUNX1 mutations was also prognostic of event-free survival and overall survival109. These 
proof of principle studies clearly demonstrated the feasibility of sequencing-based residual 
disease detection. However, each of these genes were only mutated in a subset of AML cases and 
broad application of NGS as a residual disease detection modality required expanding 
sequencing to encompass the spectrum of somatic mutations in AML. 
Subsequent studies have expanded somatic mutation detection at remission using WGS 
or WES, attempting to predict relapse risk by assessing clonal expansion after therapy. A study 
of 50 patients sequenced at remission with enhanced exome sequencing (exome sequencing 
supplemented with capture reagents for AML-specific genes) or targeted capture of diagnosis-
specific variants determined that mutation persistence was associated with an increased risk of 
relapse, shorter relapse-free survival and reduced overall survival111. Interestingly, this study 
characterized a mutation as cleared if it was not detected above 0.025 VAF, the limit of detection 
for NGS, even when MPFC has demonstrated prognostic value in detecting residual AML at 
1:1,000 cells or less. Even in individuals who cleared all of their mutations at remission, median 
event free survival was still only 17.9 months. This suggested that a lower limit of detection 
would perhaps improve risk stratification by identifying rare persistent clones in individuals 
destined to relapse. In follow-up study, deeper analysis of 15 of cases identified five cases where 
clonal expansion occurred following therapy, but harbored different somatic mutations than the 
diagnostic AML sample112. These “rising clones” appeared to expand following therapy, were 
non-leukemic and did not appear related to the founding AML clone. These findings highlighted 
two additional challenges facing NGS as a platform for residual disease detection, namely, 
residual disease with prognostic value was likely present below the 0.025 VAF threshold of 
detection for NGS and clonal expansion occurred in relapse-free individuals.  
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Had these findings been known at the outset of this thesis work, the goals and design may 
have differed. However, at the genesis of this project the limit of detection for NGS appeared to 
be the primary constraint on sequencing-based residual disease detection. Specifically, the error-
rate of NGS precluded the detection of somatic mutations below approximately 0.02 VAF113. 
Based on the literature from residual disease detection with MPFC and qPCR we knew that there 
was prognostic information in detecting as few as 1:1,000-1:10,000 residual leukemic cells114–116. 
Additionally, as described previously, individuals frequently relapsed when the detection cutoff 
was 0.025 VAF or 1:20 cells for heterozygous mutations111. Fortunately, several tools had been 
recently developed to mitigate the effect of sequencing errors enabling the reliable detection of 
variants as rare as 0.0001 VAF117–125. In general, these methods capitalized on the same 
experimental trick, tag each individual DNA molecule with a unique molecular identifier (UMI), 
sequence each tagged molecule multiple times, use the UMI to identify sequence reads 
originating from the same molecule and correct the sequencing errors. These tools have been 
applied to study a variety of biological processes including HIV virus diversity124,126,  early 
detection of ovarian and endometrial cancers127, age-associated somatic mutations in 
mitochondria128, transcriptome analysis125,129, and resequencing of tumor samples for hotspot 
mutation identification130,131. Our goal was to adapt these techniques to determine whether a 
more sensitive sequencing approach that could identify rare leukemia-associated somatic 
mutations would improve residual disease detection and outcome prognostication.  
We created a novel platform for amplicon-based error-corrected sequencing (ECS) that 
enable the reliable detection of rare clonal somatic mutations. Our first application of this 
technique was through a collaboration with Daniel C. Link and Terrence N. Wong in the 
Department of Medicine at Washington University School of Medicine in St. Louis, who were 
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studying the role of TP53 mutations in therapy-related AML (t-AML) and therapy-related 
myelodysplastic syndrome (t-MDS). These diseases arise following treatment with 
chemotherapy, radiation therapy and/or immunotherapy; are marked by poor outcomes; and 
often do not respond to treatment132. At the time, the prevailing theory was that DNA damage 
introduced by antecedent cytotoxic therapy introduced the somatic mutations that drove later 
disease133. Surprisingly, tumor/normal sequencing of several t-AML/t-MDS cases did not 
identify an increased number of somatic mutations compared to de novo AML. However, they 
did observe a different spectrum of mutations with lower rates of DNMT3A, NPM1 and FLT3 
mutations and increased rates of TP53 and ABC transporter mutations. They were interested in 
determining when the leukemogenic TP53 mutations arose in the intervening years between the 
cytotoxic therapy exposure and development of t-AML/t-MDS. Shockingly, using our targeted 
ECS approach, we demonstrated that leukemogenic TP53 mutations were present at very low 
frequencies years before the development of t-AML/t-MDS and in two cases before 
chemotherapy exposure (Chapter 3)134. We subsequently used this approach to demonstrate that 
other non-TP53 mutations were present months to years before the development of t-AML/t-
MDS135. These paradigm-shifting findings suggested that the leukemia-associated mutations 
were not introduced by the chemotherapy, but were already present in the individuals and were 
selected for by the treatment. Additionally, we demonstrated that ECS could reliably detect rare 
clonal mutations below the error-rate of NGS. These findings also suggested that the detection of 
rare clonal leukemia-associated mutations in healthy individuals could predict who would later 
develop hematological malignancy.  
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1.6 Clonal Hematopoiesis in Disease-Free Individuals 
The concept of aberrant clonal expansion preceding and predicting leukemic 
transformation has grown in recent decades. Early evidence of benign clonal expansion in the 
hematopoietic compartment was demonstrated using X-inactivation studies in healthy 
women136,137. They observed that X-inactivation skewing increased as a function of age and 
presciently suggested stem cell exhaustion or clonal hematopoiesis as likely culprits. Later it was 
shown that X-inactivation skewing predominantly occurred in the myeloid compartment138. 
Subsequently, somatic mutations in TET2 were identified in individuals with hematopoietic X-
inactivation skewing, establishing a genetic cause for this phenomenon139. These findings were 
quickly bolstered by large scale microarray and sequencing studies of healthy blood samples. 
Somatic mosaicism of large chromosomal anomalies (duplications, deletions and uniparental 
disomy) was detected using microarray data from blood samples in <0.5% of individuals <=50 
years old and 2-3% of individuals >50 years old, which was associated with a 10-fold increased 
risk of developing hematological malignancy140. Similarly, a concurrent study observed clonal 
mosaicism in 2% of individuals over 50 years-old and 20% of individuals who later developed 
myeloid or lymphocytic leukemia141. While these were examples of clinically silent clonal 
expansion in healthy individuals, there are also well described benign conditions that precede 
malignancy. Monoclonal gammopathy of undetermined significance (MGUS) is a benign 
condition occurring in up to 2% of individuals 50 years-old or older and progresses to multiple 
myeloma or a related disease at a rate of 1% per year142. Similarly, monoclonal B-cell 
lymphocytosis, another benign condition, progresses to CLL at a rate of 1.1% per year143. Recent 
genome sequencing efforts have sought to determine the spectrum of somatic mutations driving 
clonal hematopoiesis and understand the additional steps required for transformation into 
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fulminant malignancy. One study examined the normal blood samples analyzed as control tissue 
from 2,728 participants in The Cancer Genome Atlas project and identified 77 clonal blood-
specific somatic mutations in 58 individuals144. These clones frequently harbored mutations in 
leukemia-associated genes such as DNMT3A, TET2 and JAK2 and were more prevalent in older 
individuals. Two subsequent reports characterized clonal hematopoiesis in two large (>12,000 
person) cohorts unselected for hematological malignancy and observed that clonal hematopoiesis 
increased with age (rare at 50 years-old and present in approximately 10% of 70 year-olds) and 
frequently harbored mutations in DNMT3A145,146. Interestingly, they only observed the canonical 
leukemia-associated DNMT3A R882H mutation in a sixth of clones with a DNMT3A mutation 
compared to two thirds of AML cases with a DNMT3A mutation45,145. An additional report 
studying hot spots recurrently mutated in AML demonstrated that clonal hematopoiesis 
harboring DNMT3A R882H/R882C and JAK2 V617F mutations arose in younger-aged 
participants and mutations affecting spliceosome genes arose in older participants147. In an 
interesting case report, WGS of a single 115 year-old woman’s blood suggested that the majority 
of her hematopoietic compartment originated from two clonally related HSCs, as they identified 
two clusters of somatic mutations at 0.22 and 0.32 VAF148. Even the Welch et al. report 
describing clonal evolution of AML observed leukemia associated mutations in the blood of 
health individuals, which became more prevalent with age62. This type of clinically silent benign 
clonal expansion has been termed clonal hematopoiesis of indeterminate potential (CHIP)149. 
Despite these provocative findings, all of these studies could only detect common 
hematopoietic clones due to the error-rate of NGS. We sought to characterize the prevalence and 
spectrum of mutations below the detection limit of NGS and establish whether these mutations 
arose in long-lived HSPCs or more terminally differentiated cells. Fortunately, in our ill-fated 
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efforts to create a platform for sequencing-based residual disease detection, we had created the 
perfect tools to answer this question. Through collaboration with the Nurses’ Health Study at 
Brigham and Women’s Hospital and Harvard University, we were able to study serially banked 
blood samples from healthy women. Characterizing these samples with targeted error-corrected 
sequencing, we discovered that clonal hematopoiesis is a ubiquitous finding by middle age and 
revealed new insights into the biology or normal and leukemogenic clonal hematopoiesis 
(Chapter 4)150.  
Together this body of work demonstrates the inherent complexity of hematopoiesis and 
leukemogenesis. Outlined in these chapters are the steps we took to develop our platform for 
error-corrected sequencing (Chapter 2) and the discoveries made with this technology (Chapters 
3&4). This process has been an exciting and humbling experience. It is fascinating and terrifying 
to think that everybody has a hematopoietic compartment chock-full of expanding clones 
harboring leukemogenic mutations by middle age. Yet, AML is such a rare disease that virtually 
all of these clones must benignly co-exist with their host. Witnessing this phenomenon makes me 
optimistic for the future, when we will have to tools and knowledge to accurately predict which 
clonal mutations, groups of mutations or epigenetic signatures are harbingers of disease and 
which mark stable benign clonal hematopoiesis. 
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Chapter 2: Creating a Platform for Targeted 
Error-Corrected Sequencing 
2.1 Introduction 
Our initial goal was to develop a sequencing-based modality for residual disease 
detection in cases of AML. Specifically, we sought to replace MPFC—the gold standard for 
residual disease detection—because it was only useful in a subset of individuals and insensitive 
to clonal diversity. In contrast, a sequencing-based approach would be applicable in virtually 
every case of AML and sensitive to the clonal diversity present within an individual’s tumor. 
This platform would target some or all of the leukemia-specific somatic mutations present in 
persistent leukemic and pre-leukemic clones that survived therapy and could initiate relapse. 
Additionally, founder mutations—the initiating lesions acquired early during leukemogenesis—
would tag all leukemia-specific clones and a subset of pre-leukemic clones that could initiate 
relapse. 
We initially viewed the sequencing error rate of NGS, which precluded detection of 
SNVs rarer than 0.02 VAF, as the predominant limitation of sequencing-based residual disease 
detection113. Conversely, MPFC, when applicable, provided prognostic information to a 
detection limit of 1 leukemic cell in 1,000 total cells93. At the outset of this project, one NGS-
based residual disease detection study had achieved a limit of detection similar to MPFC by 
targeting indel events in FLT3 and NPM1110. This was possible because indel errors were rarely 
made by the NGS platform. Unfortunately, SNVs occur approximately 10-times more frequently 
than indels in AML56. Likewise, the sensitive detection of SNVs was essential to capture the 
spectrum of somatic mutations in leukemic clones. To address this limitation, we focused on 
improving the limit of detection for accurate SNV calling.  
21 
 
Fortunately, when we began this project, two papers had been recently published that 
circumvented the error-rate of NGS using unique-molecular identifiers (UMIs)117,120. One 
method termed Safe-SeqS tagged each strand of individual DNA fragments with a unique 12- or 
14-base random oligonucleotide index (UMI) during library preparation120. When sequenced, 
multiple sequence reads containing the same UMI originated from the same original single-
stranded DNA molecule. Computationally, these reads were compared to each other and 
sequencing errors present in a single read were corrected by comparison to the other reads from 
the same original tagged molecule. This mitigated the effect of sequencing errors and enabled the 
detection of mutations as rare as 0.001 VAF for most classes of substitutions. Specifically, the 
limit of detection for G to T and C to T mutations was still closer to 0.01 VAF due. The source 
of these errors are described below. Despite this limitation, we developed our targeted error-
corrected sequencing (ECS) approach based on these techniques.  
Another method termed Duplex Sequencing enabled a lower limit of detection than Safe-
SeqS by tagging both strands of each DNA fragment with complementary UMIs117. While every 
double-stranded DNA (dsDNA) molecule in the library was tagged with a different UMI, each 
complementary strand comprising a single dsDNA molecule was tagged with a complementary 
UMI. This enabled linking of sequenced reads from each strand of the original dsDNA molecule, 
enabling the correction of strand-specific artifacts and PCR errors introduced early during library 
preparation. Interestingly, by tagging both complementary DNA strands, they were able to 
demonstrate that most errors present in libraries only UMI-tagging single-strands of DNA (e.g. 
Safe-SeqS) were due to DNA damage. Specifically, they observed guanine oxidation to 8-
oxoguanine (G to T mutations) and cytosine deamination to uracil (C to T mutations), which 
were both well characterized mechanisms of DNA degradation151,152. When DNA was treated 
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with an oxidizing agent, they observed an increase in G to T mutations in single-strand 
consensus sequences, but not in duplex consensus sequences117. Unfortunately, this improvement 
in error-correction required four times more sequencing than the Safe-SeqS methods. While 
useful in in small model systems (e.g. the mitochondrial genome), Duplex Sequencing was not 
suited to target large regions of the human genome. Conversely, the Safe-SeqS approach could 
be adapted to enable the identification of clonal somatic mutations in all of the recurrently 
mutated genes in AML.   
Having settled on a framework for generating ECS libraries, we next developed methods 
to target specific loci in the genome. Previous applications of ECS were in small systems 
(mitochondrial DNA, plasmids) that could be sequenced entirely. To apply these techniques for 
residual disease detection in patients with AML, we needed to target specific loci in the genome. 
Initially, we attempted this using liquid-phase hybridization capture with biotinylated 
oligonucleotide baits, which was the primary capture strategy for exome sequencing153. This 
method enabled sampling from diverse, randomly sheared genomic DNA libraries and avoided 
many of the issues found with PCR amplification (jackpotting, allelic skewing). However, we 
were totally unsuccessful. The capture yield for individual targets was exceptionally low and the 
off-target rate was unacceptably high. Granted we were trying to capture a handful of loci 
(hundreds of bp) from the entirety of the genome (3 billion bp), so even a 1000-fold enrichment 
by capture still resulted in an unusable library.  
We next moved on to PCR-based capture. This method could reliably capture individual 
exons from the genome, variant calls were quantitative, and PCR artifacts were minimal. This 
technique enabled targeted-ECS for our collaboration with Dan Link and Terrence Wong 
(Chapter 3), studying TP53 mutations in therapy-related AML (t-AML). We were able to 
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identify variants identified at diagnosis for t-AML at low frequency in samples banked years 
prior to diagnosis. However, with this method, we still noticed a high rate of G to T substitutions, 
indicative of guanine oxidation to 8-oxoguanine in the primary sample. Initially, this precluded 
the detection rare clonal G to T substitutions. However, we later developed a binomial statistical 
framework to model position specific error profiles. This enabled us to identify likely clonal G to 
T (and C to T) mutations above the background error rate due to DNA damage artifacts. For 
other substitutions, this model us to reliably identify variants as rare as 0.0001 VAF.  
The effect of DNA damage was also observed in artefactual false positives observed in 
our validation experiments using droplet digital PCR (ddPCR)154. With this technique, DNA was 
partitioned into microfluidic droplets that were genotyped individually. Genotyping was 
accomplished by amplification with primers spanning the variant of interest and querying with a 
variant-specific TaqMan probe. Droplets receiving a copy of the wild-type allele would fluoresce 
with the wild-type probe and droplets receiving a copy of the mutant allele would fluoresce with 
the mutant probe. Occasionally, we observed droplets that received two different alleles from 
separate genomic DNA molecules. These double-positive droplets occurred at predicable, low 
rates. However, when the wild-type allele was guanine and the mutant allele was thymine 
(guanine oxidation), we observed many more double-positive droplets than expected by chance. 
The same was true for cytosine to thymine substitutions (cytosine deamination). Due to these 
known sources of artifacts, we modified Bio-Rad’s approach to calculating VAF to improve the 
accuracy of rare variant quantification.  
The final set of methods that we developed were for multiplex capture with ECS. PCR-
based capture, described previously, enabled targeting at a handful of loci within a single sample. 
This was useful when resequencing samples with known mutations. However, a different 
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approach was required to create a single reagent that could detect rare leukemia-associated clonal 
mutations in nearly all individual with AML. A broad panel was necessary as every case of AML 
contains a different spectrum of somatic mutations and the clonal mutations that drive relapse are 
often undetectable at diagnosis56,64. We combined the Illumina TruSight Myeloid panel with our 
ECS library preparation to enable rare variant detection at multiple loci recurrently mutated in 
AML. With this reagent, we targeted a tractable subset of the genome (141 kb covering 54 
genes) that covered recurrently mutated loci in AML. By combining these two protocol, we were 
able to reliably detect leukemia-associated variants as rare as 0.0003 VAF. Unfortunately, our 
initial application of this technology as a modality for residual disease detection ended in failure. 
We received a bad lot of reagents from Illumina that introduced an unacceptably number of PCR 
artifacts during library preparation. While initially unsuccessful, future planned studies in the lab 
will compare targeted-ECS to MPFC for residual disease detection in AML. 
While applied here to the study of AML and clonal hematopoiesis, these tools are broadly 
applicable for rare variant detect with any set of genes and in any tissue type. Presented here are 
some of the key experimental successes and failures conducted to develop our targeted error-
corrected sequencing protocol. 
2.2 Protocol Development 
2.2.1 General principles for ECS 
Our adaptation of error-corrected sequencing built upon the established Safe-SeqS 
design120. In general, DNA molecules were tagged with unique molecular identifiers (UMIs), 
amplified by PCR and sequenced to yield multiple sequenced reads per original tagged molecule. 
Sequencing errors present at one position in one of the sequenced reads would be identified by 
observing the correct nucleotide call in the other reads originating from the same tagged 
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molecule (Figure 2.1). Practically, random 16-bp UMIs were introduced into the standard 
Illumina Y-shaped adapters (Figure 2.2). These adapters were ligated to genomic DNA 
fragments during library preparation such that each molecule was tagged with a different UMI. 
Multiple identical copies of each tagged molecule were created by PCR amplification. This 
amplified library was then submitted for sequencing. After sequencing, the reads originating 
from the same original molecule were grouped together based on their UMI sequence. Initially, 
we allowed up to two mismatches per UMI to allow for sequencing errors in the 16-bp UMI 
sequence. However, further analysis demonstrated that the UMI sequences were not as random 
as advertised by Integrated DNA Technologies, our oligonucleotide vendor. Allowing a UMI 
mismatch correction frequently grouped together reads from two separate uniquely tagged 
molecules that differed in UMI sequence by only a single nucleotide (Figure 2.3). Based on these 
observations, we did not allow mismatches in the UMI sequence when generating read 
families—groups of reads originating from the same tagged molecule. 
Several parameters of the ECS library preparation protocol were determined 
experimentally. One critical parameter was library concentration after ligation with the UMI-
tagged adapters. In the t-AML study, library concentration was quantified using quantitative 
PCR (qPCR). Later, experiments used ddPCR to more accurately quantify library concentration. 
Regardless, successful rare variant detection with ECS absolutely required that multiple copies 
of each original UMI-tagged molecule were sequenced concurrently. Likewise, the number of 
UMI-tagged molecules had to be accurately restricted before a final amplification step, so 
amplicons would be sequenced for each tagged molecule. If the library was too dilute, 
sequencing bandwidth would be wasted with too many reads covering a handful of UMIs. 
Conversely, if the library was too concentrated then each UMI would only be covered by a single 
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read at most, preventing error-correction by multiple sequence alignment. This calculation was 
based on the sequencing bandwidth of the machine run planned, the number of samples 
multiplexed on the run, the number of targets per samples, the number of sequenced reads per 
UMI, and the desired limit of detection. After several experiments, we decided that 10x coverage 
per UMI resulted in the optimal balance between sequencing coverage per UMI and number of 
UMI-tagged molecules per library. The remaining parameters were decided for each unique 
experiment. For example, to target a single-loci in a single sample with an Illumina MiSeq Nano 
(1M reads) run, the library must contain 100,000 UMI-tagged molecules that would be amplified 
for sequencing. If the calculation was incorrect and 500,000 molecules were selected instead, the 
average coverage per UMI would only be 2x and the results would be uninterpretable. Given the 
precision required at the steps, extra care was taken to accurately quantify library concentration 
before dilution.  
The second set of parameters that factored into experiment planning were the number of 
genome equivalents entering the reaction, the expected yield of capture and the desired limit of 
detection. In the previous example, to query 100,000 genome equivalents, the reaction needed to 
start with 330 ng of human genomic DNA (3.3 pg per haploid human genome). Capture 
efficiencies varied dramatically depending on the targeting protocol. For the clonal 
hematopoiesis studies (Chapter 4), the capture reagent had a capture efficiency of approximately 
5%. Based on that estimate, we used 250-500 ng of input DNA (75,000-150,000 genome 
equivalents) to ensure a limit of detection of at least 1:1,000 variant allele fraction (VAF). 
Reducing the amount of input DNA would worsen the limit of detection irrespective of 
sequencing depth. 
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Several other bioinformatics parameters we empirically derived. We established a 
minimum read family size of five reads. Other groups had generated read families from two or 
three reads sharing the same UMI120. However, we found a lower false positive rate when using a 
higher minimum read family size. Additionally, we required that 90% of the reads present at a 
given position within a read family call the same nucleotide to call a consensus nucleotide, 
otherwise we reported an N at that position. Finally, consensus sequences were not reported if 
more that 10% of the positions were called as an N. We found that modifying these last two 
parameters did not significantly affect the specificity of the variant calls. While the capture 
methods differed significantly over the projects presented here, the fundamental parameters for 
read family generation and variant calling remained constant. 
2.2.1 Co-opting liquid-phase hybridization capture for ECS 
The first attempt at selecting genomic loci for targeted ECS was with liquid-phase 
hybridization capture (Figure 2.4). With this method, randomly sheared genomic DNA was 
hybridized to biotinylated oligonucleotide baits (complementary to a region of interest). 
Genomic DNA fragments hybridizing to the biotinylated baits were captured with streptavidin 
coated magnetic beads. These steps were identical to standard exome capture protocols. The 
adapter sequences were designed to be compatible with the Illumina sequencing chemistry 
(Figure 2.2). While standard exome sequencing often targeted 30-70 Mb or approximately 1% of 
the human genome, we sought to target individual regions that were approximately 300 bp long 
or 0.00001% of the human genome. Initially, this didn’t seem like such a foolish idea, but 
hindsight tells a different story of youthful optimism. Using 90-bp long oligonucleotide baits 
(Table 2.1), we attempted to recreate the hybridization conditions used with standard exome 
capture. The primary experimental condition that we varied was the molar ratio of bait molecules 
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to target loci in the genomic DNA. We initially started with a bait:target molar ratio of 100:1, but 
did not pull down any DNA. Subsequently, we tested molar ratios of bait:target from 105:1 to 
109:1 using 8 baits simultaneously for a single locus (Table 2.2). The optimal molar ratio was 
107:1, where we observed approximately 10% of the reads were on target. However, these reads 
were generated from only a couple hundred molecules and reported coverage was inflated by 
sequencing PCR duplicates of these few molecules. Alone, the low on target rate would have 
been acceptable. However, few of the genome equivalents present in the hybridization reaction 
were successfully captured for sequencing. We started these experiments with 500 ng of genomic 
DNA, which was approximately 150,000 genome equivalents. After accounting for PCR 
duplicates, we recovered at most 500 distinct molecules from the targeted reaction or 0.3% of 
target genome equivalents present. As outlined previously, this low capture efficiency precluded 
the detection of rare clonal mutations. 
We attempted to improve capture efficiency by reversing the adapter ligation and capture 
steps. We believed the adapter sequences, especially the long UMI index, would interfere with 
the hybridization stoichiometry or lead to daisy-chaining. Daisy-chaining occurred when one 
molecule was hybridized correctly to a biotinylated bait, but the adapter sequence for that 
molecule was hybridized to another molecule that would be unintentionally pulled down in the 
capture step. Theoretically, by reversing the steps, only fragmented genomic DNA would be 
captured by the baits without the risk of daisy-chaining. However, this was unsuccessful because 
too little DNA was captured for the subsequent library preparation steps. To troubleshoot this 
problem, we added synthesized amplicons during the ligation step to improve the ligation 
stoichiometry. These amplicons all contained uracil instead of thymine and we degraded after 
ligation with uracil DNA glycosylase (Figure 2.5). Unfortunately, this was also unsuccessful as 
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the synthetic amplicons that escaped cleavage by UDG were more than enough to overwhelm the 
few captured genomic DNA molecules.  
Given this limitation of liquid-phase hybridization capture, we were forced to abandon 
this as a method for capturing genomic loci. For sequencing-based residual disease detection, we 
required reliable identification of genomic variants from one leukemic cell out of 1,000 normal 
cells. Given the limitations observed, the amount of input genomic DNA necessary to achieve 
this limit of detection was unreasonably high. Likewise, we redirected our efforts to different 
methods for capturing genomic loci.  
2.2.3 PCR amplification-based targeting of genomic loci 
We next sought to capture individual loci from genomic DNA using PCR primers 
spanning the region of interest. This was a much easier method than the original liquid phase-
hybridization capture, but there were several potential drawbacks. First, errors introduced during 
the early steps of PCR amplification, before UMI-tagging, would be indistinguishable from true 
rare variants. Second, PCR jackpotting could skew allelic ratios, especially for the low frequency 
variants we intended to detect155. Jackpotting occurred when a low number of template 
molecules were not uniformly amplified during PCR. The most extreme example is the loss of a 
constitutional heterozygous polymorphism due to selective amplification of one allele, which 
frequently occurs during whole genome amplification. To circumvent this limitation, we split 
template samples into eight separate reactions for amplification, mixed the samples back together 
after purification and then repeated the process. This allowed us to dilute out the effect of 
jackpotting. Additionally, we used the Q5 High-Fidelity DNA Polymerase (NEB) to minimize 
the number of error introduced during PCR amplification. 
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The general workflow for amplicon-targeted ECS was straightforward (Figure 2.6). 
Primers were designed to target regions of interest (e.g. exons 4-7 of TP53). The resulting 
amplicons were individually tagged with UMI-containing adapter sequences by ligation. The 
libraries were diluted to restrict the number of molecules seeding the sequencing run, amplified 
by PCR and then submitted for sequencing. The resulting sequenced reads were grouped into 
read families based on their UMI, sequencing errors were identified, and an error-corrected 
consensus sequence was generated.  
2.2.4 Multiplex hybridization-extension-ligation for leukemia-associated 
target capture 
PCR amplification-based capture enabled the analysis of up to about a dozen loci 
simultaneously. The primary limitation to targeting more loci with PCR was the amount of 
starting template material required. To detect rare clonal mutation (at 0.001 VAF) approximately 
500 ng of genomic DNA was required per experiment. Other methods could target up to 50 loci 
simultaneously by introducing a pre-amplification step with all of the primers followed by 
individual amplification with each primer pair156. However, for our study of clonal 
hematopoiesis in healthy individuals (Chapter 4), we needed to increase the number of target loci 
by yet another order of magnitude to query all of the recurrently mutated genes in AML. Our 
ultimate goal was to develop a broadly applicable platform for residual disease assessment in 
AML. This broad utility hinged on being able to detect leukemia-associated mutations in virtual 
every unique case of AML.  
To accomplish this goal, we sought to adapt our error-corrected sequencing indexing 
strategy to a pre-existing capture reagent that had been already balanced and benchmarked. 
Ultimately, we selected the Illumina TruSight Myeloid Panel, which targeted 141 kb of the 
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human genome with 568 amplicons in 54 genes. The method for capture was similar to 
molecular inversion probes, where primers were designed to span a given locus of interest and 
anneal to the same strand of DNA (Figure 2.7a-c)130. Beginning from the upstream primer, a 
single step of extension would fill in the gap between the primers (Figure 2.7b). Next a ligation 
step would connect the filled in strand with the annealed downstream primer (Figure 2.7c).  
Similar to the Y-shaped adapters described previously, these capture primers each had 
asymmetrical, non-complementary tails that were compatible with the Illumina sequencing 
chemistry. While the sequences of the Y-shaped adapters were reported by Illumina, they did not 
disclose the sequences flanking each primer pair in the TruSight Myeloid panel. When we tried 
to use our existing UMI adapter chemistry with the TruSight Myeloid panel, the library 
preparation failed. We suspected that the adapter sequences had changed, but Illumina could not 
confirm our suspicions. Since we could not use the standard TruSight Myeloid adapters for ECS, 
we needed design our own compatible UMI-adapters. We determined the Illumina adapter 
design by Sanger sequencing a library generated with the standard TruSight Myeloid protocol 
and subsequently designed our own UMI-adapters (Figure 2.8). With this information, we 
continued adapting ECS to the TruSight panel (Figure 2.7d-g). We used PCR to add in our 
custom designed adapter sequences that contained a fixed-index for sample multiplexing and a 
UMI-index to enable ECS. Once these molecules were generated, the same process of accurate 
quantification, dilution, amplification, sequencing and analysis were conducted to call rare 
variants. This platform was used for novel rare variant detection in our study of clonal 
hematopoiesis in healthy individuals (Chapter 4).  
We conducted several experiments to assess library quality and technical reproducibility. 
We determined that the coverage per target was highly concordant between the standard Illumina 
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TruSight Myeloid protocol and our modified protocol to introduce adapters with UMIs (Figure 
2.9). We also observed that coverage per target was highly correlated between replicate libraries 
produced from the same samples (Figure 2.10). We also observed that generating the error-
corrected consensus sequence did not bias coverage per amplicon. While some amplicons were 
covered poorly in these experiments, they were covered poorly with the standard protocol as 
well. These findings demonstrated that the ECS protocol integrated into the TruSight Myeloid 
protocol without disrupting the capture efficiency.  
2.2.5 Binomial error modelling 
The predominant limitation of our method for error-corrected sequencing was that only 
single strands of DNA were UMI-tagged. Likewise, we could not correct substitutions 
originating from DNA degradation of the original template or early PCR errors. The errors that 
we observed were usually G to T substitutions, due to guanine oxidation to 8-oxo guanine, and C 
to T substitutions, due to cytosine deamination to uracil. We modeled the prevalence of these 
artifacts to observe their position-specific distribution to potentially distinguish rare variants 
from artifacts introduced by DNA damage.  
Surprisingly, we observed a strong position specific effect on the substitution error rate. 
While the G to T substitution rate varied widely across a specific region, the error rate at a single 
position was consistent between samples. Based on this observation we modeled the position 
specific error profile as a binomial process, analogous to a coin-flipping experiment. The variant 
calls made by the error-corrected consensus sequences (ECCSs) were treated as a series of coin 
flips. If we observed 1000x coverage at a given position, that corresponded to 1000 coin flips. At 
each independent position, we counted ECCSs identifying the wild-type or variant nucleotide 
(heads vs tails). By sequencing multiple individuals and replicates, we could build a robust 
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model of the substitution error rate at every position captured by the panel. Thus, for each variant 
observed in a sample, we could estimate the probability that variant was artefactual given the 
error profile at that position.  
We also accounted for multiple hypothesis testing to reduce the rate of false positive 
calls. Since the capture panel targeted 141 kb of sequence and there were three substitution types 
per position, there were almost half a million hypothesis tests per sample. We employed a 
stringent Bonferroni correction on our variant calls that corrected for the number of samples, 
replicates, bases covered and substitution classes in the entire cohort. As a result, our variant 
calls were highly specific. While the sensitive of the assay was never directly assessed, this 
statistical framework likely grossly underreported the number of true rare variants present. 
Conversely, every substitution called by ECS, that we subsequently validated with ddPCR, was 
observed at nearly identical VAFs (Chapters 3 and 4).  
2.2.6 Validation with ddPCR 
Given the extremely low VAFs identified by ECS, we needed an equally sensitive 
method for validation. While expensive to implement, we use the Bio-Rad QX200 ddPCR 
platform to validate our findings. This technology combined allele-specific TaqMan probes with 
microfluidic partitioning to permit extremely sensitive and specific variant quantification. 
Similar to ECS, the primary constraint on the limit of detection was the number of genome 
equivalents used in the assay. Experimentally, primers and probes were designed to target a 
specific single nucleotide variant or small indel. Genomic DNA was partitioned into microfluidic 
droplets such that on average one or fewer genome equivalents of the region of interest was 
present in a single droplet. The region of interest was amplified by PCR and subsequently 
assayed with the allele-specific TaqMan probes. The droplets were then analyzed to assess 
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fluorescence intensity for the wild-type or variant probe. Variant calls as rare as 0.0001 VAF 
were easily validated on this platform. For negative controls, we selected samples from the same 
cohort where the variant of interest was not observed. Surprisingly, we frequently observed zero 
positive mutant droplets in our negative control experiments, which often had up to 500,000 total 
droplets. 
Interestingly, the platform was so sensitive that we observed the effect of DNA 
degradation on our genomic DNA samples. These were predominantly C to T (cytosine 
deamination) and G to T (guanine oxidation) mutations, as described previously. These artifacts 
manifested as a higher number of “double positive” droplets than expected in experiments with a 
G to T or C to T mutation. These double positive droplets arose normally when a droplet was 
formed containing a wild-type genomic DNA fragment and a fragment harboring the variant. We 
could estimate the number of expected double positive droplets from the frequency of wild-type 
only and variant only droplets because they were independent processes that followed a Poisson 
distribution. To prevent these artefactual double-positive droplets from inflating the VAF 
estimated by ddPCR, we ignored the double positive droplets during analysis. Instead, we 
estimated the VAF from the number of mutant only positive droplets and the Poisson estimated 
number of singleton droplets. Since the variants were rare we assumed that variant positive 
droplets only contained a single genome equivalent of the variant allele. Likewise, we calculated 
the VAF by dividing the number of variant only droplets by the estimated number of droplets 
containing one genome equivalent of genomic DNA, which harbored either the wild-type or 
variant allele. For low frequency variants, where the rate of cytosine deamination could double 
or triple the estimated VAF, this method provided a more accurate approximation of the VAF. 
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This method was used for validation experiments in both the t-AML study (Chapter 3) and the 
study of clonal hematopoiesis in healthy individuals (Chapter 4). 
2.3 Discussion 
These are some of the key experiments undertaken to develop our platform for targeted 
ECS-based rare variant detection. These experiments underlie the decisions made regarding 
choice of reagents, protocol design and bioinformatics analysis. These parameters were not 
selected randomly. We strove to enable leukemia-associated rare variant detection in the most 
efficacious manner possible. Every decision was a compromise that optimized many factors 
including cost of sequencing, efficient biospecimen use, ease of application, breadth of utility, 
limit of detection and false positive rate. For example, we opted not to implement Duplex 
Sequencing because we did not believe the lower limit of detection was worth the dramatically 
higher cost of sequencing and amount of input material required. To compensate, the statistical 
framework for variant calling was very stringent to reduce the rate of false positive variant calls. 
Conversely, many true positives were likely missed.  
There are many ways to improve this technology. Future development of targeted-ECS 
could proceed down several avenues. First, the efficiency of capture could be dramatically 
improved. We used the Illumina TruSight Myeloid panel to target genomic loci that were 
recurrently mutated in AML. While almost all of the captured molecules were on target, only 
approximately 5% of the genome equivalents present were captured. Liquid-phase hybridization 
capture had many off target reads and poor capture efficiency. As capture technology improves, 
it will directly benefit the detection of rare clonal mutations.  
Second, improvements to the sequencing technology may make capture unnecessary. 
Instead of targeting regions of interest and accepting the limitations of capture, whole genome 
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ECS would enable the unbiased identification of rare clonal mutations. Already, one study 
sequenced UMI-tagged molecules from a whole genome library preparation to demonstrate that 
somatic mutation rates differ based on age and tissue of origin157. As throughput increases and 
cost decreases these types of studies may become more feasible. 
Third, single-cell sequencing technology has the potential to revolutionize this field. With 
our approach, we could not determine which rare variants co-occurred in the same cells. Robust 
single cell sequencing could cleanly describe how clonal mutations are partitioned within a 
biological sample, such as a tumor, peripheral blood or sorted stem cells. Already, these 
techniques have been applied crudely to describe clonal architecture in pediatric ALL and pre-
leukemic clonal hematopoiesis79,85,86. However, these studies relied on bulk sequencing to 
identify the somatic mutations that were re-sequenced in single cells. Improvements in single-
cell genomic DNA isolation and capture would enable a new world of discovery into the biology 
of clonal hematopoiesis.  
In conclusion, the technology developed here enabled the characterization of previously 
undetectable rare hematopoietic clonal mutations. We have further refined our understanding of 
the intricate and complicated biological processes that underlie stem cell homeostasis, clonal 
evolution and leukemogenesis. Fortunately, the technology is advancing rapidly and studies that 
are now strictly theoretical will soon become feasible. 
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Figure 2.1 General schematic for error-corrected sequencing. a) Individual molecules of 
genomic DNA were tagged with a unique molecular identifier (blue and magenta). b) PCR 
amplification and sequencing produced multiple sequenced reads from each originally tagged 
molecule. Errors introduced by PCR or by sequencing (yellow) were randomly distributed across 
the sequenced reads. c) By comparing the sequenced reads from the same original molecule 
(marked by the same UMI) the sequencing errors were identified and corrected revealing true 
variant (red).    
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Figure 2.2 Adapter sequences that enabled error-corrected sequencing. The two sequences in 
black were the Y-shaped Illumina adapter sequences. The homopolymer run of N’s in the top 
half of the Y-shaped adapter encoded the random unique molecular identifier for each adapter 
sequence. The bottom half of the Y-shaped adapter was a fixed sequence. In blue were the PCR 
primers that amplify these molecules during library preparation after the ligation step. The other 
colored-coded sequences were the Illumina-specific sequencing primers. Sequences were placed 
to demonstrate annealing orientation. The star denoted the 5-prime end of the oligonucleotides 
and the lower-case “p” denoted the phosphorylated 5-prime end of the adapter, which enabled 
ligation.  
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Figure 2.3 Hamming distance correction in UMI sequence. Each plot depicted the histogram of 
read family sizes (sequenced reads that shared the same UMI). The top and bottom rows depicted 
the same data with different scales on the y-axis. As the hamming distance increased, the number 
of read families of size one decreased, which indicated that indexes with a single nucleotide error 
in the UMI were correctly grouped. However, these histograms also demonstrated that many 
average-sized read families were collapsed with a hamming distance of 1 or 2. This suggested 
that the UMI sequences were not as random as originally thought.  
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Figure 2.4 Hybridization capture with biotinylated baits. Genomic DNA was sheared into 300 
bp fragments. Adapters were ligated to the fragmented DNA molecules that contained random 
unique molecular identifiers for error-corrected sequencing. Hybridization-capture pulled down 
the fraction of the library in the region of interest based on the biotinylated oligonucleotide baits. 
These captured fragments were amplified and sequenced.  
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Figure 2.5 Troubleshooting Illumina Y-shaped adapter ligation. a) Under normal conditions, 
DNA fragments (black) and Y-shaped adapters (green) were in favorable molar ratios resulting 
in the ligation of one adapter to each end of the DNA fragments. b) When too few DNA 
molecules were present, adapter dimers formed instead. c) Adding synthesized amplicons (cyan) 
containing uracil to the few captured DNA fragments improved the ligation stoichiometry. The 
synthetic amplicons were degraded by uracil DNA glycosylase (UDG) after the ligation step. 
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Figure 2.6 Schematic for amplicon-targeted error-corrected sequencing. Step 1: Amplification of 
genomic DNA with target-specific primers (green arrows) yielded a subset of amplicons 
containing a rare clonal mutation (red). Step 2: Randomly indexed adapters (tan and orange) 
were ligated to each amplicon. Step 3: Read families containing the same index sequence 
originated from a single UMI-tagged molecule. Sequencing errors (yellow) were randomly 
distributed across the sequenced reads within a read family. Step 4: Multi-sequence alignment of 
reads within a single read family enabled the identification of sequencing errors and the 
subsequent generation of an error-corrected consensus sequence.  
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Figure 2.7 Illumina TruSight Myeloid capture and error-corrected sequencing. a) Primers 
(black) designed to flank a region of interest were annealed to genomic DNA (blue). b) Single 
strand extension filled in the nucleotides between the two primers, recording the genomic 
information from the template molecule. c) Ligation connected the extended strand to the 
downstream primer. d) The single hybridization-extension-ligation step enabled the simultaneous 
capture of 568 amplicons from the genomic DNA sample. e) The ends of each primer were 
compatible with the Illumina sequencing chemistry. We introduced the sequencing adapter and a 
fixed sample-specific index (cyan) using PCR directed to one end of the captured molecule. f) 
We introduced another sequencing adapter containing the random UMI index (green) to the other 
end of the molecule with PCR. g) The resulting molecules were then further prepared for 
sequencing.   
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Figure 2.8 Illumina TruSight Myeloid adapter sequences revealed by Sanger sequencing. By 
designing Sanger sequencing primers that annealed within one of the target regions, we were 
able to sequence out into the adapter sequence and determine the differences between the 
TruSight Myeloid adapter and the original Y-shaped Illumina adapter. The known Y-shaped 
adapter sequences (grey) were used to map the Sanger reads from both sequencing experiments. 
a) The upstream (i5) adapter sequence contained the index sequence we wished to replace with 
our random UMI index. Sanger sequencing of the adapter (alignments in black in the box, 
mismatches in cyan) revealed that the TruSight Myeloid kit used the same i5 adapter. b) The 
downstream (i7) adapter sequence contained the fixed index sequence we used for sample 
multiplexing. Sanger sequencing of the adapter (alignments in black in the box, mismatches in 
cyan) revealed that the i7 adapter sequence was different than the original Y-shaped adapter. 
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Figure 2.9 Coverage per target amplicon for standard vs ECS protocol. Sequencing of a library 
prepared with the Illumina TruSight Myeloid kit protocol (x-axis) was compared to the modified 
protocol to incorporate UMIs and ECS (y-axis). Coverage per amplicon was highly concordant 
between the two protocols.  
  
47 
 
 
Figure 2.10 Coverage per target amplicon for two replicate ECS libraries. While the second 
experiment had more total coverage (y-axis), coverage per target was highly correlated with the 
first experiment (x-axis). 
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Table 2.1 Biotinylated baits example. These baits were designed for an early experiment 
targeting TP53 exon 7. The 5’-biotin label was denoted as /5Biotin/.  
 
Target Sequence 
P53exon7
Bait1 
/5Biotin/ATGGGTAGTAGTATGGAAGAAATCGGTAAGAGGTGGGCCCAGGGGTCAGAGGCAAGCAGAG
GCTGGGGCACAGCAGGCCAGTGTGCAGGG 
P53exon7
Bait2 
/5Biotin/TCAGAGGCAAGCAGAGGCTGGGGCACAGCAGGCCAGTGTGCAGGGTGGCAAGTGGCTCCTG
ACCTGGAGTCTTCCAGTGTGATGATGGTG 
P53exon7
Bait3 
/5Biotin/TGGCAAGTGGCTCCTGACCTGGAGTCTTCCAGTGTGATGATGGTGAGGATGGGCCTCCGGTTC
ATGCCGCCCATGCAGGAACTGTTACAC 
P53exon7
Bait4 
/5Biotin/AGGATGGGCCTCCGGTTCATGCCGCCCATGCAGGAACTGTTACACATGTAGTTGTAGTGGAT
GGTGGTACAGTCAGAGCCAACCTAGGAG 
P53exon7
Bait5 
/5Biotin/ATGTAGTTGTAGTGGATGGTGGTACAGTCAGAGCCAACCTAGGAGATAACACAGGCCCAAGA
TGAGGCCAGTGCGCCTTGGGGAGACCTG 
P53exon7
Bait6 
/5Biotin/ATAACACAGGCCCAAGATGAGGCCAGTGCGCCTTGGGGAGACCTGTGGCAAGCAGGGGAGG
CCTTTTTTTTTTTTTTTTGAGATGGAATC 
 
  
49 
 
Table 2.2 Biotinylated bait capture efficiency. The capture efficiency for hybridization capture 
for 8 baits designed against TP53 exon 7. Capture efficiency was poor throughout the 
experiment. At a bait:target molar ratio of 107:1 the on target fraction was close to 10%, however 
these reads were PCR duplicates from only a couple hundred captured molecules.  
 
Molar Ratio Bait:Target On Target Reads Total Reads Fraction 
109:1 366 136,991 0.0027 
108:1 9,522 145,036 0.0657 
107:1 12,267 126,691 0.0968 
106:1 418 166,583 0.0025 
105:1 1,615 117,851 0.0137 
NC 0:1 2 201,205 0 
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Chapter 3: Rare Pre-Leukemic Clone 
Detection in Therapy-Related AML 
3.1 Introduction 
The quantification of rare clonal and subclonal populations from a heterogeneous DNA 
sample has multiple clinical and research applications for the study and treatment of leukemia. 
Specifically, in the hematopoietic compartment, recent reports demonstrate the presence of 
subclonal variation in normal and malignant hematopoiesis63,148, and leukemia is now recognized 
as an oligoclonal disease62. Currently, clonal heterogeneity in leukemia is studied using next-
generation sequencing (NGS) targeting subclone-specific mutations. With this method, detecting 
mutations at 0.02-0.05 variant allele fraction (VAF) requires costly and time-intensive deep re-
sequencing and identifying lower-frequency variants is impractical regardless of sequencing 
depth. Recently, various methods have been developed to circumvent the error rate of NGS117,120. 
These methods tag individual DNA molecules with unique oligonucleotide indexes or unique 
molecular identifiers (UMIs), which enable error-correction after sequencing.  
Expanding upon these techniques, we developed methods for error-corrected sequencing 
(ECS) that enabled the study of clonal heterogeneity during leukemogenesis. We benchmarked 
these methods with dilution series experiments, which demonstrated quantitative SNV detection. 
Separately, the ECS error-profile revealed highly specific variant detection down to 1-2:10,000 
molecules for all substitutions, except for G to T transversions. These substitutions were only 
detectable down to 1:500 due to oxidative DNA damage in the original samples.  
As a pilot study for potential clinical utility, we applied ECS to identify leukemia-specific 
mutations in banked pre-leukemic blood and bone marrow samples from patients who later 
developed therapy-related acute myeloid leukemia (t-AML) or therapy-related myelodysplastic 
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syndrome (t-MDS). These diseases occur in 1-10% of individuals who receive alkylator- or 
epipodophyllotoxin-based chemotherapy or radiation to treat a primary malignancy132. For the 
nine individuals surveyed in this study, matched leukemia/normal whole genome sequencing 
identified the t-AML/t-MDS-specific somatic mutations present at diagnosis. We applied our 
method for ECS to identify leukemia-specific mutations in six out of nine individuals using DNA 
extracted from blood and bone marrow samples collected years prior to diagnosis.  
Results from two of these individuals (UPN530447, UPN341666) were published in a 
study specifically describing the role of TP53 mutations in the development of t-AML/t-MDS134. 
Surprisingly, in two separate individuals in that study (not reported here), clonal TP53 mutations 
were detected before chemotherapy exposure, changing the established theory of leukemogenesis 
in t-AML/t-MDS. Previously, the chemotherapy or radiation exposure was thought to directly 
introduce the somatic mutations necessary for the development of t-AML/t-MDS133. Instead, 
these mutations were likely acquired in the hematopoietic compartment stochastically over the 
patient’s lifetime and not introduced by therapy. This presented a testable hypothesis: were 
clonal TP53 mutations detectable in the blood of healthy elderly individuals? Using our error-
corrected sequencing approach for novel variant discovery (instead of resequencing known 
mutations), we demonstrated that 9/19 healthy elderly individuals harbored clonal TP53 
mutations in their peripheral blood.  
Results from the remaining seven individuals were published in a subsequent study that 
expanded upon the methodological advancements made to enable rare pre-leukemic clone 
detection. In two of these seven individuals, clonal mutations were identified below the 1% 
threshold of detection governed by conventional NGS. These results highlighted the ability of 
targeted-ECS to identify clinically silent single nucleotide variations (SNV).  
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3.2 Methods 
3.2.1 Study Design 
Blood and bone marrow samples from patients treated for t-AML/t-MDS at Washington 
University were banked or accessed following informed consent under Human Research 
Protection Protocol #201011766. Patients included in this study underwent matched leukemia 
and non-cancer (skin) whole genome sequencing on the Illumina HiSeq 2500 platform, which 
identified tumor-specific somatic coding mutations in leukemia samples. Our study focused on 
identifying these known mutations from matched blood or bone marrow samples banked 1-13 
years prior to the initial diagnosis of t-AML/t-MDS.  
3.2.2 Sample Preparation 
Genomic DNA was isolated from either FFPE or cryopreserved peripheral blood or bone 
marrow samples using the QIAamp DNA FFPE Tissue or DNA Mini Kit (Qiagen). PCR primers 
were designed using primer3158 to amplify regions harboring individual leukemia-specific 
mutations from the banked biological samples (Table 3.1). The concentration of each purified 
DNA sample was determined using the Qubit dsDNA HS Assay Kit (Life Technologies). 
Genomic DNA (400-800 ng) was amplified using the Q5 High-Fidelity 2X Master Mix (New 
England Biolabs) in a 25 uL reaction with 0.5 uM primers (Figure 3.1a). The following 
conditions were used: 98C for 30s; 16-30 cycles of 98C for 10s, 62-72C (based on a separate 
optimization) for 30s and 72C for 30s; 72C for 2m; hold 10C. The PCR reactions were purified 
using the Agencourt AMPure XP (Beckman Coulter) bead-based protocol without modification.  
For a few of the patient samples, the amount of input genomic DNA was limited. In these 
cases, modifications were made to the protocol to amplify multiple leukemia-specific mutations 
from the same biological sample (multiplex PCR). Patient-specific primers were pooled during a 
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first round of PCR and amplified for roughly 16 cycles, similar to pre-amplification described in 
TAm-Seq156. After purification the DNA was split into a single PCR reaction per patient-specific 
SNVs and amplified using only that specific primer pair, again for roughly 16 cycles. This 
allowed us to generate diverse amplicon pools for multiple loci using only 400-800 ng of starting 
DNA.  
3.2.3 ECS Library Preparation 
The concentration of the purified PCR products was measured using the Qubit dsDNA 
HS Assay Kit (Life Technologies). NGS libraries were prepared from 800 ng of amplicons for 
each sample/mutation using the Illumina TruSeq DNA Sample Preparation Kit (Illumina). We 
replaced the Illumina-provided Y-shaped adapters with custom adapters containing a random 16 
base pair oligonucleotide index sequence (Table 3.2). Adapters were diluted to 40 uM in Tris-
EDTA with 5 nM NaCl and annealed using the following conditions: 95C for 5m then decreased 
by 1C every 30s to 4C. Aside from the custom adapters used for ligation, the library preparation 
protocol from Illumina was mostly unchanged (Figure 3.1b). Enrichment for correctly ligated 
products was completed using a 50 uL Q5 PCR amplification with 2 uL of ligation product and 
0.5 uM Illumina specific primers under the following conditions: 98C for 30s; 6 cycles of 98C 
for 10s, 57C for 30s and 72C for 30s; 72C for 2m; hold 10C The PCR reaction was purified 
using a modified Ampure bead cleanup, which increased the size range of purification to remove 
adapter dimers. 100 uL of beads were washed twice with ddH2O to remove the stock poly-
ethylene glycol (PEG) solution. The solution was replaced with 25.5 uL 50% wt/vol PEG 
(Sigma), 37.5 uL 5M NaCl and 37 uL ddH2O. The PCR reaction was added to this solution and 
purified per the standard Ampure protocol.   
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3.2.4 Quantification by qPCR 
We sought to generate read families from a single randomly-indexed molecule with 
roughly seven-fold coverage. Given the bandwidth of a single Illumina MiSeq run was roughly 
15-18 million read pairs, we sought to generate sequencing libraries from roughly 2.5 million 
molecules. To achieve this, we quantified the concentration of each library using the qPCR NGS 
Library Quantification Kit, Illumina GA (Agilent Technologies). Based on the measured 
concentration, each library was diluted to 0.4 pM such that a 10 uL volume of the diluted library 
would contain ~2.5 million molecules. The 10 uL aliquot of diluted sequencing library was then 
amplified for 16-20 cycles and purified with the same Q5 and modified Ampure bead protocol 
used for the previous enrichment PCR step. The final library was visualized on a 2% SYBR Safe 
gel (Life Technologies) and quantified using Qubit dsDNA HS Assay Kit. When multiplexing 
samples on a single lane of sequencing, individual sequencing libraries were combined in 
equimolar amounts after enrichment PCR and the pooled sample was diluted and quantified 
using qPCR as stated previously. However, we also found it possible to pool amplicons in 
equimolar amounts after the initial genomic DNA amplification and make a single sequencing 
library. Up to 7 different amplicons were multiplexed on a single MiSeq run. Multiplexing was 
only possible with mutations in different genes or within different exons of the same gene 
because the samples were demultiplexed by alignment. 
3.2.5 Sequencing 
Each library was sequenced on the Illumina MiSeq instrument as specified by the 
manufacturer (Figure 3.1c). Approximately, 5-10% of PhiX control DNA was spiked into each 
sequencing experiment. Each completed sequencing run contained roughly 15-18M paired-end 
150 bp reads. Raw sequence reads were aligned to the PhiX genome using Bowtie 2159. Sequence 
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reads aligning to PhiX were removed from further analysis. The remaining sequence reads were 
aligned to UCSC hg19/GRCh37 using Bowtie 2 for comparison against error-corrected 
consensus sequences (ECCS) derived from read families (below). 
3.2.6 Error Corrected Consensus Sequences 
Sequence reads containing the same index sequence (originated from the same randomly-
indexed molecule) were aligned to each other to generate read families in a fashion similar to 
previously published methods117,120 (Figure 3.1d). Previous studies used a minimum read family 
size of three117. We found using a more stringent cutoff of five reduced the error rate in the read 
families (Figure 3.2). The median read family size was seven reads per index (Figure 3.3). 
Paired-end reads within a read family were error corrected in a stepwise fashion (Figure 3.1e). 
First, at every position, the nucleotides called by each sequence read were compared and a 
consensus nucleotide was called if there was at least 90% agreement between the reads. If there 
was less than 90% agreement, an N was called in the consensus sequence at that position. Errors 
that occurred during library preparation and sequencing were removed because they were not 
shared between different reads within a read family. Second, an ECCS was thrown out if less 
than 90% of the 300 nucleotides comprising the paired-end read were assigned a non-N 
nucleotide. These ECCSs were locally aligned to UCSC hg19/GRCh30 using Bowtie2159 (Figure 
3.1f). The aligned ECCSs were processed with Mpileup160 using the parameters –BQ0 –d 
10000000000000. This removed the coverage thresholds to ensure that all of the pileup output 
was returned regardless of variant allele fraction (VAF) or coverage. Variant allele factions 
comprised of both the expected mutations and the background errors for each sample were 
visualized using IGV161 and graphically represented using ggplot2162. Each known variant was 
plotted relative to the error-profile of that specific substitution class (e.g. an expected C to T 
56 
 
transition was compared against the C to T error profile). Variants distinguishable from the noise 
for that specific error class and located at the expected position within the amplicon were called 
true positives. The threshold for calling true variants varied based on the error profile of that 
substitution class. Based on our benchmarking studies we were 99% specific to detect variants 
above 0.0034 VAF for G to T (C to A) substitutions, 0.00020 VAF for C to T (G to A) 
substitutions and 0.000079 VAF for the other eight possible substitutions.  
3.2.7 Healthy control methods 
Amplicons were prepared from healthy control genomic DNA samples using primers 
designed to amplify exons four through eight of TP53 (Table 3.3). Patient specific barcodes, six 
nucleotides in length, were appended to the 5-prime end of each primer to enable pooling of 
multiple samples for sequencing. Amplicons generated from each TP53 exon/patient sample 
combination were generated as previously described and purified products were pooled in 
equimolar amounts. The pooled barcoded amplicons were prepared for error-corrected 
sequencing as previously described. Sequencing was completed on the Illumina Hi-Seq 2500 
platform. Sequenced reads were demultiplexed based on the known patient-specific barcode 
sequences using a two nucleotide hamming distance. Demultiplexed sequence reads were 
organized into read families based on their random oligonucleotide index sequence and error-
corrected as outlined previously. Read families comprised of three reads or more were used for 
analysis. A binomial distribution of the substitution rate at each covered base in TP53 was used 
to identify individuals with TP53 mutations. A variant was called if the binomial p-value was 
less than 10-6, the VAF was greater than 1:10,000, the individual read family coverage was 
greater than 10,000x, at least 10 read families called the variant and the VAF in the individual 
was greater than five times the mean VAF for all individuals with greater than 10,000x coverage 
57 
 
at that specific nucleotide. Read families from one patient sample (barcode GTACGGC) were 
removed from analysis due to a high error rate.  
3.3 Results 
3.3.1 Design and Validation 
We employed ECS by tagging individual DNA molecules with adapters containing 16 bp 
random oligonucleotide molecular indexes in a manner similar to other reports117,120,163. Our 
implementation of ECS easily targeted loci of interest through single or multiplex PCR and 
inserted seamlessly into the standard NGS library preparation (Figure 3.1). Our only deviations 
from the standard protocol were ligation of customized adapters containing random indexes 
instead of the manufacturer’s supplied adapters and a qPCR quantification step prior to 
sequencing (Table 3.2). Following sequencing, sequence reads containing the same index and 
originating from the same molecule were grouped into read families. Sequencing errors were 
identified by comparing reads within a read family and removed to create an error corrected 
consensus sequence (ECCS).  
We performed two dilution series experiments to assess bias during library preparation 
and determine the limit of detection for ECS. For the first experiment, we spiked DNA from a t-
AML sample into control human DNA, which was serially diluted over five orders of magnitude. 
The experiment was comprised of two technical replicates targeting two separate mutations (20 
total independent libraries). The results demonstrate that ECS is quantitative to a VAF of 
1:10,000 molecules and provides a highly reproducible digital readout of tumor DNA prevalence 
in a heterogeneous DNA sample (r2 of 0.9999 and 0.9991, Figure 3.4). A second dilution series 
experiment using a leukemia sample with a somatic TP53 H179L mutation highlighted the 
background rate of G to T (C to A) substitutions that likely arose from DNA damage in the 
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original samples (Figure 3.5). The limit of detection for ECS was approximately 0.002 VAF and 
the limit of detection for substitutions other than G to T (C to A) was approximately 0.0002 VAF 
(Figure 3.6).  
3.3.2 Error Profile of Error-Corrected Consensus Sequences 
We next characterized the error profile based on the wild-type nucleotides included in the 
first dilution series experiment. Variant identification using the ECCSs was 99% specific at a 
VAF of 0.0016 versus 0.0140 for deep sequencing alone (Figure 3.7a). We noticed that ECCS 
errors were heavily biased towards G to T transversions and to a lesser degree C to T transitions 
(Figure 3.7b, Figure 3.8), as previously observed117,122. When separated by substitution type, 
variants identified from the ECCSs were 99% specific at a VAF of 0.0034 for G to T (C to A) 
mutations, 0.00020 for C to T (G to A) mutations and 0.000079 for the other eight possible 
substitutions. While excess G to T mutations were a known consequence of DNA oxidation 
leading to 8-oxo-guanine conversion117, the pre-treatment of samples with 
formamidopyrimidine-DNA glycosylase (Fpg) prior to PCR amplification did not appreciably 
improve the error profile of G to T mutations (Figure 3.9).  
3.3.3 Rare Clonal Mutation Detection in Pre-Leukemic Samples 
As proof of principle, we applied ECS to study rare pre-leukemic clonal hematopoiesis in 
nine individuals who later developed t-AML/t-MDS. Leukemia/normal whole genome 
sequencing at diagnosis was used to identify the leukemia-specific somatic mutations in each 
patient’s malignancy (Table 3.4). We applied targeted ECS to query these 26 different loci in 12 
cryopreserved or formalin-fixed paraffin-embedded (FFPE) blood and bone marrow samples that 
were 9-22 years-old and banked up to 12 years prior to diagnosis (Table 3.5).  
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We generated approximately 50 Gb of 150 bp paired-end reads from 11 Illumina MiSeq 
runs. We targeted 1-7 somatic mutations per individual (26 mutations spanning 6.5 kb from 18 
genes in total) and identified leukemia-specific clonal populations in six individuals up to 12 
years prior to diagnosis (Table 3.6). For each sequencing library, we tagged approximately 2.5 
million locus-specific amplicons generated from genomic DNA using high-fidelity PCR with 
UMI-indexed custom adapters. Sequencing errors were removed to create ECCSs as described 
above. Each ECCS was then aligned to the reference genome for variant calling (Figure 2.6). 
Using conventional deep sequencing, we detected t-AML/t-MDS-specific mutations in 
prior banked samples at variant allele fractions between 0.03 and 0.87 (data not shown). In one 
individual (UPN 684949), deep sequencing alone was insufficient to distinguish known ASXL1 
and U2AF1 mutations from the sequencing errors in samples banked five and three years prior to 
t-MDS diagnosis, respectively (Figure 3.10a,b). However, ECS identified the L866* nonsense 
mutation in ASXL1 at a VAF of 0.004 (Figure 3.10c) and the S34Y missense mutation in U2AF1 
at a VAF of 0.009 (Figure 3.10d). In addition, ECS was able to temporally quantify these 
mutations from three pre-t-MDS samples banked yearly from 3 to 5 years prior to diagnosis 
(Figure 3.11, Figure 3.12). In two cases (UPN643006 and UPN942008), only a subset of the 
variants identified at diagnosis were present in the prior banked sample (Table 3.6). Specifically, 
in the UPN643006 sample, banked twelve years prior to diagnosis, a single nucleotide deletion in 
ASXL1 was present at VAF 0.03. But, the G to T substitution in ASXL1, CTT deletion in GATA2 
and G to T substitution in U2AF1 were not detectable in this prior banked sample. In two 
additional cases TP53 mutations were detected prior to the developed of t-AML/t-MDS. In 
UPN530447, somatic TP53 K139N and TP53 R248Q mutations were detected six years prior to 
t-AML diagnosis at 0.007 VAF and 0.005 VAF, respectively (Figure 3.13). A co-occurring 
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CSMD1 mutation was also detected in the prior-banked sample at 0.004 VAF. But, the NUP98 
Q1532H and TET2 K1299M mutations that were detected at t-AML diagnosis were not detected 
in the prior-banked sample. In UPN341666, a TP53 R196* mutation was detected at 
approximately 0.001 VAF three years prior to the development of t-MDS (Figure 3.14). 
Interestingly, a RUNX1 W279* mutation that co-occurred at t-MDS diagnosis was not detected 
in the prior-banked sample, suggesting that this mutation was acquired later during the 
development of disease. 
3.3.4 Rare Clonal TP53 Mutations in Healthy Individuals 
The frequency and profile of somatic single nucleotide mutations in the hematopoietic 
stem cells (HSCs) of normal individuals have been previously measured62. The number of 
somatic mutations increased with age and was estimated to occur at a rate of 3.2 x 10-9 
mutations/nucleotide/year (95% CI 2.4-4.0 x 10-9) for the average nucleotide in the exome. Thus, 
we predicted that an average 50-year-old person would have 1.6 x 10-7 mutations/position. These 
mutations would not be randomly distributed but biased towards C to T (G to A) transitions62. 
Previous studies have proposed that an individual possesses approximately 10,000 distinct 
HSCs164. We used a randomized Monte Carlo simulation to model the prevalence of somatic 
single nucleotide mutations in healthy 50-year-old individuals with 10,000 HSCs given a normal 
somatic mutational profile and mutation rate. Repeated simulation (n=100,000) allowed us to 
predict the distribution of aging-induced TP53 somatic mutations. As expected, this simulation 
modeled a Poisson process. Mutations were deemed detrimental if they had a SIFT score less 
than 0.05 and on a list of putative driver TP53 mutations37,38,165. Using this simulation, we 
predicted that 44% of 50-year-old individuals harbored one or more HSCs with a detrimental 
TP53 mutation (Figure 3.15). We likely underestimated that number of functional TP53 
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mutations per individuals, as we are accounting only for single nucleotide somatic missense 
mutations in our model. Insertions, deletions, nonsense mutations, and splicing-altering 
mutations are not accounted for. Thus, 44% is likely a lower estimate for the number of healthy 
individuals with a detrimental TP53 somatic mutation in at least one HSC.   
We also sought to experimentally determine the number of hematopoietic stem and 
progenitor cells (HSPCs) harboring TP53 mutations in healthy individuals. We analyzed 
peripheral blood leukocytes from 20 elderly (68–89 years old) cancer-free donors, who had not 
received prior cytotoxic therapy. We targeted the DNA binding domain of TP53 (exons 4-8) as 
most leukemogenic mutations occurred in this region. Using ECS, we identified TP53 mutations 
in 9 of 19 evaluable cases, at 0.0001 VAF to 0.0037 VAF (Table 3.7). We used droplet digital 
PCR to validate these findings in all three cases tested. Most mutations detected had been 
observed previously in malignancy based on the COSMIC dataset37,38. Interestingly, we likely 
underreported the number of functional TP53 mutations in healthy individuals because we only 
targeted a subset of the coding sequence and did not detect indel or splicing mutations. These 
findings suggested that somatically acquired functional TP53 mutations in HSPCs may confer a 
subtle competitive advantage over time even without cytotoxic exposure.  
3.4 Discussion 
Here, we present a practical and clinically oriented application for targeted error-
corrected NGS utilizing unique molecular identifiers (UMIs). This method easily integrated into 
existing NGS library preparation protocols and enabled the quantification of previously 
undetectable mutations in heterogeneous DNA samples. The only modification to the standard 
NGS library preparation was the replacement of the stock adapters with our randomly indexed 
adapters and the addition of a qPCR step before sequencing. The qPCR step limited the number 
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of molecules sequenced, ensuring adequate coverage for each read family. With these two 
modifications, we achieve highly specific detection for rare mutations. The bioinformatics 
analysis was straightforward and did not require proprietary algorithms or tools (Supplementary 
Methods). Our results highlight the ability of this method to identify rare subclonal populations 
in a heterogeneous biological sample. As applied to t-AML/t-MDS, we demonstrated these 
previously undetectable mutations were present years prior to diagnosis and fluctuated in 
prevalence over time.  
A clinical application of ECS is to quantify minimal residual disease (MRD). As the 
genomic characterization of leukemia becomes more readily available, identifying causative 
genetic lesions and rare therapy-resistant subclones will become increasingly useful for risk 
stratification, therapeutic selection and disease monitoring. Already, whole genome sequencing 
of AML has demonstrated that nearly every case of AML harbors one or more somatic single 
nucleotide variations (SNV)56. These SNVs are more reliable clonal markers of malignancy than 
cell surface markers, which can change over time. Leveraging this information, conventional 
NGS was implemented retrospectively to detect residual disease harboring leukemia-specific 
insertions/deletions (indels) as rare as 0.00001 VAF in NPM1108 and 0.0001 VAF in RUNX1109. 
This was possible because indels were only rarely generated erroneously by NGS. Unfortunately, 
measuring rare leukemia-associated substitutions is limited due to the relatively high error profile 
of conventional NGS166. However, ECS can achieve the 1:10,000 limit of detection featured by 
conventional MRD platforms116. For patients whose leukemia lacks suitable markers for 
conventional MRD, ECS could offer an alternative with comparable sensitivity and specificity 
that is easy to implement in a clinical sequencing lab. Furthermore, the ability to multiplex 
targets for ECS enables the surveillance of known mutations and the simultaneous discovery of 
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new somatic mutations. Ongoing work will directly compare gold-standard MRD methods to 
targeted ECS in patients with and without relapsed leukemia. 
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Figure 3.1 Schematic for amplicon-targeted error-corrected sequencing. a) Primers designed to 
span a locus of interest enabled the recovery of variants (orange) in that region. b) Adapter 
sequences containing a unique molecular identifier (UMI) were ligated to each captured 
amplicon. c) Amplification and sequencing for a restricted subset of these UMI-tagged 
molecules produced multiple sequenced reads per UMI. Sequencing errors (yellow) were 
randomly distributed across the sequenced reads. d) These errors were distinguishable from the 
correctly sequenced nucleotide in other reads from the same read family. e) Correcting the 
sequencing errors produced an error-corrected consensus sequence. f) The comparison of 
multiple error-corrected consensus sequences from different UMI-tagged read families enabled 
the detection of rare variants present below the error rate of conventional sequencing. 
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Figure 3.2 Error profile observed with increased read family size. Read families generated with 
3x or greater coverage (solid line) had a higher cumulative distribution of erroneous substitutions 
called compared to read families with 5x or greater coverage (dotted line). 
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Figure 3.3 Representative distribution of read family size. Singletons predominantly represented 
index sequences containing a sequencing error. Excluding singletons, the median read family 
size was 7x (mean 7.4x). Only read families with 5-20 reads were included in ECS analysis. 
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Figure 3.4 Benchmarking for ECS and the identification of rare pre-leukemic mutations. DNA 
extracted from a diagnostic leukemia sample with known mutations in a) RUNX1 and b) IDH2 
was serially diluted into non-cancer, unrelated human DNA. Two replicates were analyzed per 
sample/dilution. The coefficient of determination (r2) between diluted tumor concentration in the 
sample and VAF in the generated read families was 0.9999 and 0.9991 for RUNX1 and IDH2, 
respectively. 
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Figure 3.5 Second dilution series experiment. A leukemia sample with a somatic TP53 H179L 
mutation at 0.37 VAF was serially diluted with normal genomic DNA as described by the labels 
on the left. The observed VAFs across the amplicon of interest with conventional sequencing 
(left panels) or error-corrected sequencing (middle and right panels) were plotted. Artifacts due 
to guanine oxidation lead to an increased rate of C to A (G to T) mutations. These data were also 
analyzed after removing C to A (G to T) substitutions as the variant of interest was a T to A 
substitution (right panel). The TP53 variant allele was circled in blue. 
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Figure 3.6 Threshold of variant detection for the second dilution series experiment. Given the 
second dilution series experiment, this was that range of detection for mutant alleles relative to 
the error rates of raw sequencing reads (red) and error-corrected read families (yellow). A DNA 
damage-specific C to A (G to T) error bias was observed in the read families. Sensitivity was 
further improved after removing C to A (G to T) substitutions (blue).  
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Figure 3.7 Characteristics of substitutions called from the error-corrected sequencing 
experiments. a) The VAF at every nucleotide not expected to contain somatic mutations in the 
first dilution series experiment were analyzed to determine the error profile of the error-corrected 
consensus sequences compared to conventional deep sequencing. A cumulative distribution 
function of VAF demonstrated a reduced error-profile in read families relative to conventional 
deep sequenced reads. b) The most frequent class of substitution seen in read families was the G 
to T (C to A) transversion, which was consistent with oxidative conversion of guanine to 8-oxo-
guanine. 
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Figure 3.8 Cumulative distribution function of the error profile comparing error-corrected 
sequencing to conventional deep sequencing.  The variant allele fraction for each non-variant 
position covered in the dilution series experiment was sorted and plotted cumulatively. The 
variant allele fractions of errors were higher in every nucleotide covered across all substitution 
types for the raw sequenced reads compared the error-corrected consensus sequences generated 
from read families. 
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Figure 3.9 Cumulative distribution function of read family error profile per specific substitution 
type with and without FPG pretreatment. The error profile of G to T (C to A) substitutions, 
consistent with guanine oxidation to 8-oxo guanine, was higher than the other classes of 
mutations. The C to T (G to A) substitutions, consistent with cytosine deamination to uracil, was 
visible just over the error profile for the remaining 8 types of substitutions (inset). FPG 
pretreatment did not appreciably change the error profile.  
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Figure 3.10 Identification of rare clonal ASXL1 and U2AF1 pre-leukemic mutations. a,b) The 
leukemia-specific variants identified in ASXL1 and U2AF1 at diagnosis (circled) were not 
distinguishable from sequencing errors in the same substitution class by conventional deep 
sequencing. c,d) Targeted error-corrected sequencing identified the ASXL1 variant in the 2002 
banked sample at 0.004 VAF and the U2AF1 variant in the 2004 banked sample at 0.009 VAF.  
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Figure 3.11 ASXL1 mutations over time in UPN684949. Formalin-fixed paraffin-embedded bone 
marrow samples were banked over three years from this individual. a-c) Conventional deep 
sequencing only distinguished the ASXL1 variant from the T to G sequencing errors in the 2003 
banked sample at 0.097 VAF. d-f) Correcting the sequencing errors with ECS identified the 
ASXL1 variant at 0.0042 VAF in 2002, 0.092 VAF in 2003 and 0.029 VAF in 2004. 
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Figure 3.12 U2AF1 mutations over time in UPN684949. Formalin-fixed paraffin-embedded 
bone marrow samples were banked over three years from this individual. a-c) Conventional deep 
sequencing only distinguished the U2AF1 variant from the G to T sequencing errors in the 2003 
banked sample at 0.036 VAF. d-f) Correcting the sequencing errors with molecular indexing did 
not identify the U2AF1 variant in 2002, but did identify the U2AF1 variant at 0.031 VAF in 2003 
and 0.0089 VAF in 2004.  
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Figure 3.13 Rare clonal somatic mutations identified by error-corrected sequencing in individual 
UPN530447. Rare clonal TP53 K139N and TP53 R248Q mutations were detected at 0.007 VAF 
and 0.005 VAF, respectively (blue circles). These mutations were not distinguishable from the 
sequencing errors in the raw reads (row 1), but detectable in the error-corrected read families 
(row 2). The frequency of other mutations detected at t-AML diagnosis was also measured. The 
CSMD1 mutation was observed at 0.004 VAF in the error-corrected read families and not 
distinguishable from sequencing noise in the raw reads. The NUP98 Q1532H and TET2 K1299M 
mutations were not detected.  
  
77 
 
 
Figure 3.14 Rare clonal somatic mutations identified by error-corrected sequencing in individual 
UPN341666. A clonal TP53 R196* mutation was identified at 0.0009 VAF (blue circle). This 
mutation was not distinguishable from the sequencing errors in the raw reads (row 1) or read 
families (row 2). However, removing systematic C to A (G to T) substitution errors enabled 
identification of the true mutation above the noise threshold (row 4). A RUNX1 W279* mutation 
that was detected at diagnosis was not detected in prior-banked sample. The raw sequencing 
results (row 3) and read family results (row 5) for a control sample without the mutations were 
included for comparison.  
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Figure 3.15 Simulated burden of predicted damaging TP53 mutations in hematopoietic stem 
cells (HSCs) from healthy 50-year-old individuals. Using Monte Carlo simulation (n=100,000) 
with the observed exome-wide mutation rate and substitution distribution, we estimated that 
approximately 44% of healthy 50-year-old individuals had at least one HSC with a detrimental 
TP53 mutation. The randomly distributed mutations were deemed detrimental if the SIFT score 
was less than 0.05 and the mutation was a putative TP53 driver mutation. 
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Table 3.1 Primers targeting leukemia-specific variants. Primer sequences used to generate 
variant-specific amplicons from banked genomic DNA samples.  
 
UPN Gene FWD Primer Reverse Primer 
341666 TP53 CCCAGGCCTCTGATTCCTCAC GGCCACTGACAACCACCCTTAACC 
 RUNX1 GGAAAGTTCTGCAGAGAGGGTTGTCAT CCTTTCTGATTCTCTTCAGATACAAGGC 
446294 OBSCN GGAGCCTCTGACCCTGCATCCCTCC CCCGCCTCACAGCTGTACTCCCCAG 
 
TP53 AGACCTCAGGCGGCTCATAGGGCAC GGGGCTGGAGAGACGACAGGGCTG 
499258 RUNX1 
TCACTAGAATTTTGAAATGTGGGTTTGTTG
CC 
GCACTCTGGTCACTGTGATGGCTGGC 
530447 TP53 K139N AGTTGCTTTATCTGTTCACTTGTGC CTCCGTCATGTGCTGTGACTGC 
 TP53 R248Q CCCTGCTTGCCACAGGTCTCC AGTGTGCAGGGTGGCAAGTGG 
 CSMD1 AAAGCATCTCCAAAACCATTGCCCTGCC AAAATCCGGTACAGCTGCCTCCCTG 
 NUP98 GCAGGAGGACAAAGATGGCCCAC GACTACCGCCTAAGCTGGCACTTG 
 TET2 TGGGTCATCCCCAAGCAGCTTAAAC CAGGAGAACTTGCGCCTGTCAGG 
574214 DMD GGCGATGTTGAATGCATGTTCCAGT AGGACTATGGGCATTGGTTGTCAAT 
643006 ASXL1 GGACCCTCGCAGACATTAAAGCCCGT GCCTCACCACCATCACCACTGCTGC 
 
GATA2 CCACAGGTGCCATGTGTCCAGCCAG CTGTGGCGGGGTGGGAGGAATGTTG 
 
U2AF1 
TGAACACAAATGGAAAATACAACTACGAG
AGAAAA 
CCCAGCAAAATAATCAGCTCTCATTTTC
CC 
684949 ASXL1 
CACTATGAAGGATCCTGTAAATGTGACCC
C 
TGGTTTGGGCTGTTTCACTACCTCA 
 
U2AF1 
TGAACACAAATGGAAAATACAACTACGAG
AGAAAA 
CCCAGCAAAATAATCAGCTCTCATTTTC
CC 
856024 S100A4 CCACGTGGGGACTCACTCAGGCA AATAAGACGGTCTCTGTGCCTCCTG 
 
IGSF8 TGGTACACGCCTTCATCCTCGGG GCTCAGCTCTGTCCCTGCCCAGCT 
 
PLA2R1 ACCCTGGTGTCTGTGGCATTCTCTG AGTCACAGCATCATTCCTCTTGCGGT 
 
POU3F2 CAAATGCGCGGCTCCTTTAACCGGA GCGTGGCTGAGCGGGTGTCC 
 
ANKRD18B TACCACATTCGGGACTGGGAACTGC CTCCCAGGGTCCCGGCGAACTCC 
 
ESR2 TGGCAATCACCCAAACCAAAGCATCGGT AACCCAGATCACCTCGGAGCAGGCG 
 
FBN3 GGGGACACAGTTCGCAGGGGTC GACTGGGGTGCGGGAGGTCACAGG 
942008 IDH2 GGCGTGCCTGCCAATGGTGATGGG CCGTCTGGCTGTGTTGTTGCTTGGGG 
 
RUNX1 ACATGGTCCCTGAGTATACCAGCCT GGCCACCAACCTCATTCTGTTTTGT 
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Table 3.2 Random 16-mer molecular indexed adapters. A terminal 5-prime phosphorylation on 
the complementary adapter sequence was used to enable ligation (*). 
 
Label Sequence 
16N Index 
Adapter 
AGACGGCATACGAGATNNNNNNNNNNNNNNNNGTGACTGGAGTTCAGA
CGTGTGCTCTTCCGATCT 
Complementary 
Adapter 
*GATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGC
CGTATCATT 
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Table 3.3 Primers used for amplification of TP53 DNA binding domain in healthy individuals. 
 
Primer Sequence 
4a fwd GGATACGGCCAGGCATTGAAGTCTCA 
4a rev ACCCAGGTCCAGATGAAGCTCCCAG 
5 fwd GCCCTGTCGTCTCTCCAGCCCCAG 
5 rev GACTTTCAACTCTGTCTCCTTCCTCTTCCT 
6 fwd GGCCACTGACAACCACCCTTAACCCC 
6 rev GGCCTCTGATTCCTCACTGATTGCTCTT 
7 fwd CCCAGGGGTCAGAGGCAAGCAGAGG 
7 rev CTCCCCTGCTTGCCACAGGTCTCCC 
8 fwd CCTCCACCGCTTCTTGTCCTGCTTGC 
8 rev GGGTGGTTGGGAGTAGATGGAGCCTGG 
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Table 3.4 Whole-genome sequencing of diagnosis t-AML/t-MDS samples. 
 
UPN Gene Chr Position Mutation AA Change 
Reference 
Reads 
Variant 
Reads VAF 
341666 TP53 17 7578263 G to A R196* 60 53 0.47 
 
RUNX1 21 36171728 C to T W279* 41 36 0.47 
446294 OBSCN 1 228461129 A to G H1857R 3 5 0.63 
 
TP53 17 7578271 T to A H193L 79 106 0.57 
499258 RUNX1 21 36252865 C to G R139P 122 17 0.12 
530447 TP53 17 7578513 C to G K139N 67 43 0.39 
 
TP53 17 7577538 C to T R248Q 91 109 0.54 
 
CSMD1 8 3889461 A to C G192 119 89 0.43 
 
NUP98 11 3707283 C to G Q1532H 66 59 0.47 
 
TET2 4 106180868 A to T K1299M 193 147 0.43 
574214 DMD X 32827676 G to A R187* 103 73 0.41 
643006 ASXL1 20 31022448 G to T G645C 36 32 0.47 
 
ASXL1 20 31022442 del G G645fs 33 32 0.49 
 
GATA2 3 128200135 del CTT K390in_frame_del 8 10 0.56 
 
U2AF1 21 44524456 G to T S34Y 24 27 0.53 
684949 ASXL1 20 31023112 T to G L866* 75 14 0.16 
 
U2AF1 21 44524456 G to T S34Y 57 9 0.14 
856024 S100A4 1 153517192 A to G F27L 103 48 0.32 
 
IGSF8 1 160062252 G to A P516S 28 42 0.60 
 
PLA2R1 2 160798389 A to G L1431P 45 33 0.42 
 
POU3F2 6 99282794 C to A S15R 15 15 0.50 
 
ANKRD18B 9 33524645 G to A C53Y 26 20 0.43 
 
ESR2 14 64701847 G to A A416V 40 22 0.35 
 
FBN3 19 8155081 G to A P2029L 54 38 0.41 
942008 IDH2 15 90631934 C to T R88Q 10 10 0.50 
 
RUNX1 21 36231791 T to C D171G 15 35 0.70 
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Table 3.5 Summary of patient information. The type of primary malignancy, the date of primary 
malignancy diagnosis, the date and type of blood/bone marrow banked prior to t-AML/t-MDS 
diagnosis and the date of t-AML/t-MDS diagnosis are included in the table below. At t-AML/t-
MDS diagnosis, tumor/normal whole genome sequencing identified leukemia-specific mutations. 
Some of the prior banked blood/bone marrow samples showed evidence of clonal populations 
harboring those leukemia-specific mutations before the clinical detection of disease. 
 
UPN 
Primary 
Malignancy 
Diagnosis 
Date 
Primary 
Malignancy 
Banked 
Samples 
Banking 
Type 
Date 
Banked 
t-AML/t-
MDS 
Diagnosis 
Evidence of 
Pre-Leukemic 
Subclones 
341666 NHL 04/2002 22.04 Cryo 11/2002 2005 (t-MDS) Yes 
446294 Breast cancer 2002 75.02 FFPE 07/2005 2006 (t-MDS) Yes 
499258 Hodgkin’s lymphoma 1998 24.06 Cryo 02/2002 2004 (t-MDS) No 
530447 Hodgkin’s lymphoma 1993 25.01 Cryo 02/2001 2007 (t-AML) Yes 
574214 Breast cancer 1998 26.04 Cryo 01/2000 2007 (t-MDS) No 
643006 AML 1989 80.01 FFPE 04/1992 2004 (t-MDS) Yes 
684949 CLL 09/1991 91.01 FFPE 11/2002 2007 (t-MDS) Yes 
      92.02 FFPE 09/2003   Yes 
      93.01 FFPE 10/2004   Yes 
856024 NHL 11/2004 30.02 Cryo 03/2005 2006 (t-AML) No 
942008 NHL 08/1992 33.04 Cryo 09/1996 2005 (t-AML) Yes 
      107.01 FFPE 11/2005   Yes 
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Table 3.6 Patient-specific leukemia-associated somatic mutations identified by ECS. Two to 
seven mutations were queried per individual and the number of read families (RF) containing the 
variant allele or reference allele were reported and used to calculate the variant allele faction 
(VAF). 
  
UPN 
Sam-
ple 
Yrs 
Prior Gene Chr Position Mut 
AA 
Change 
Variant 
RFs 
Reference 
RFs VAF 
341666 22.04 3 TP53 17 7578263 G to A R196* 431 500,828 0.0009 
   RUNX1 21 36171728 C to T W279* 2 99,421 0.0000 
446294 75.02 1 OBSCN 1 228461129 A to G H1857R 61,238 156,986 0.2806 
   
TP53 17 7578271 T to A H193L 220,551 110,047 0.6671 
499258 24.06 2 RUNX1 21 36252865 C to G R139P 2 486,196 0.0000 
530447 25.01 6 TP53 17 7578513 C to G K139N 3,551 489,368 0.0073 
   TP53 17 7577538 C to T R248Q 3,377 632,791 0.0053 
   CSMD1 8 3889461 A to C G192 2472 555,704 0.0044 
   NUP98 11 3707283 C to G Q1532H 97 636,713 0.0002 
   TET2 4 106180868 A to T K1299M 17 451,219 0.0000 
574214 26.04 7 DMD X 32827676 G to A R187* 7 199,945 0.0000 
643006 80.01 12 ASXL1 20 31022448 G to T G645C 7 85,781 0.0001 
   
ASXL1 20 31022442 del G G645fs 2,898 82,245 0.0340 
   
GATA2 3 128200135 
del 
CTT 
K390in_fr
_del 
0 4,187 0.0000 
   
U2AF1 21 44524456 G to T S34Y 85 414,613 0.0002 
684949 91.01 5 ASXL1 20 31023112 T to G L866* 3,583 853,598 0.0042 
   
U2AF1 21 44524456 G to T S34Y 545 514,410 0.0011 
 
92.02 4 ASXL1 20 31023112 T to G L866* 54,074 535,976 0.0916 
   
U2AF1 21 44524456 G to T S34Y 11,195 355,276 0.0305 
 
93.01 3 ASXL1 20 31023112 T to G L866* 17,319 573,629 0.0293 
   
U2AF1 21 44524456 G to T S34Y 827 92,104 0.0089 
856024 30.02 1 S100A4 1 153517192 A to G F27L 0 211,512 0.0000 
   
IGSF8 1 160062252 G to A P516S 0 22,614 0.0000 
   
PLA2R1 2 160798389 A to G L1431P 2 338,616 0.0000 
   
POU3F2 6 99282794 C to A S15R 8 201,240 0.0000 
   
ANKRD
18B 
9 33524645 G to A C53Y 7 214,836 0.0000 
   
ESR2 14 64701847 G to A A416V 10 135,861 0.0001 
   
FBN3 19 8155081 G to A P2029L 0 152,304 0.0000 
942008 33.04 9 IDH2 15 90631934 C to T R88Q 23,170 236,587 0.0892 
   
RUNX1 21 36231791 T to C D171G 40 253,168 0.0002 
 
107.01 <1 IDH2 15 90631934 C to T R88Q 138,180 161,371 0.4613 
   
RUNX1 21 36231791 T to C D171G 368,438 50,796 0.8788 
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Table 3.7 Rare clonal TP53 mutations identified in healthy individuals. Mutations were 
identified by ECS in exons 4-8 in TP53 in 9/19 healthy 50-year-old individuals. Most of the 
mutations had been observed previously in malignancy as reported in the COSMIC database. 
Three variants were also assayed by ddPCR and the expected variants were observed at similar 
VAFs (last column). 
 
ID Chr Pos Ref Var AA Change COSMIC Var RF Total RF VAF (ECS) VAF (ddPCR) 
34 17 7577505 T G D259A 
 
13 33,085 0.0004 - 
99 17 7577124 C T V272M 10891 26 81,015 0.0003 - 
99 17 7577548 C T G245S 6932 18 41,836 0.0004 - 
269 17 7577120 C T R273H 10660 489 420,026 0.0012 - 
271 17 7577209 C T Intronic 
 
36 333,996 0.0001 - 
271 17 7578413 C T V173M 11084 177 182,809 0.0010 0.0008 
271 17 7578449 C T A161T 10739 25 164,591 0.0002 - 
271 17 7579310 A T Splicing 1522474 23 165,672 0.0001 - 
273 17 7578265 A G I195T 11089 57 15,540 0.0037 0.0028 
300 17 7578190 T C Y220C 10758 91 316,765 0.0003 0.0003 
324 17 7577094 G A R282W 10704 51 86,090 0.0006 - 
335 17 7577539 G C R248G 11564 245 218,077 0.0011 - 
338 17 7577539 G A R248W 10656 188 51,001 0.0037 - 
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Chapter 4: Clonal Hematopoiesis in Healthy 
Individuals 
4.1 Introduction 
The advent of cost-effective, next-generation sequencing (NGS) has permitted in-depth 
analysis of the spectrum of somatic mutations driving clonal evolution in malignancy3,54,56. 
Subsequently, benign clonal hematopoiesis has been identified in healthy individuals136,139,143,167. 
Recent studies revealed that malignant and benign hematopoietic clones frequently harbor 
mutations in the epigenetic modifiers DNMT3A and TET256,144–147. Benign clones were rarely 
detected before 60 years old, but were detected in 10-20% of individuals older than 70 years 
old144–147. While compelling, these previous studies could only detect common clonal 
mutations—greater than 0.02 variant allele fraction (VAF)—due to the NGS error-rate. 
Hematopoietic clones detected above this 0.02 VAF threshold have been termed clonal 
hematopoiesis of indeterminate potential (CHIP) and are associated with an increased risk of 
developing hematological malignancy149. 
Recently, the development of error-corrected sequencing (ECS) using single molecule 
tagging with unique molecular identifiers (UMIs) has permitted the detection of rare variants 
below the error-rate of NGS117–120,134,135. Here, we combined ECS with targeted capture for 54 
genes recurrently mutated in acute myeloid leukemia (AML) to enable the detection of clonal 
mutations at VAFs two orders of magnitude lower than the detection limit of NGS. Using these 
methods, we sought to thoroughly describe the prevalence and mutation profile of rare 
hematopoietic clones in healthy individuals, determine if these clones are stable longitudinally, 
and determine if clonal mutations arise in long-lived hematopoietic stem and progenitor cells 
(HSPCs) or in more committed progenitors. We studied clonal hematopoiesis in longitudinally 
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banked blood samples from middle-aged healthy participants in the Nurses’ Health Study. We 
found clonal hematopoiesis, predominantly harboring mutations in DNMT3A and TET2, in 95% 
of individuals studied. Many clonal mutations were stable longitudinally and detected in both 
myeloid and lymphoid lineages, suggesting they arose in long-lived HSPCs. 
4.2 Methods 
4.2.1 Study Population 
The Nurses’ Health Study (NHS) began in 1976 with 121,701 female United States 
registered nurses age 30 to 55 years old who returned an enrollment questionnaire, which queried 
medical history, anthropometric measures, and lifestyle/environmental risk factors168. Since 
enrollment the participants have returned biennial follow-up questionnaires to update 
information on potential exposures and diagnoses of chronic disease. To date, follow-up rates 
have been consistently high (>90%). In 1989-1990, 32,826 women provided a heparinized whole 
blood sample by methods described previously169. In 2000-2001, 18,743 of the women who had 
provided a sample in 1989-1990 provided a second whole blood sample using the same 
protocol170. Briefly, participants willing to provide blood samples received kits that included all 
supplies necessary for their collection and overnight return (including a chill pack), and a brief 
questionnaire. Upon receipt, specimens were separated into plasma, buffy coat and red blood cell 
fractions and frozen in liquid nitrogen. Informed consent to participate in the NHS was implied 
by return of the enrollment and follow-up questionnaires; written informed consent was obtained 
for biomarker studies at time of blood collection.   
Among women who provided blood samples in 1989-1990 and 2000-2001, we identified 
20 with no history of cancer or other major chronic disease.  De-identified aliquots from those 40 
buffy coat samples were prepared and shipped overnight to Washington University for the 
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detection of persistent rare hematopoietic clones harboring AML-associated somatic mutations 
as described below. Since each sample was de-identified and the capture space for targeted 
genomic DNA sequencing was not enough to enable individual identification (141 kb per 
person), the Washington University Human Research Protection Office deemed this study as 
non-human research.  
4.2.2 Sample Preparation for Error-Corrected Sequencing 
Genomic DNA was extracted from 50 uL of purified buffy coat from each sample using 
the QIAmp DNeasy Blood and Tissue Kit (Qiagen) with MinElute columns (Qiagen) instead of 
standard columns to facilitate elution in a lower volume (three 30 uL elutions). The 
concentration of extracted genomic DNA was measured using the Qubit dsDNA HS Assay Kit 
(Life Technologies). Enrichment of 568 amplicons in 54 genes (141 kb) commonly mutated in 
AML was performed using 250 ng of genomic DNA via the Illumina TruSight Myeloid Panel 
(Illumina). Technical replicates were prepared for each sample (80 libraries total). Following 
extension-ligation, the amplified fragments were eluted in 50 mM NaOH. Recovered fragments 
were amplified using the Q5 High-Fidelity 2x Master Mix (New England Biolabs) in a 75 uL 
reaction (37.5 uL 2x master mix, 20 uL DNA in 50 uM NaOH, 2 uL Tris-HCl pH 7.5, 0.4 uM 
i5/i7 primers). Illumina’s standard i7 primers were used to enable sample multiplexing. The i5 
primer was redesigned to contain a random 16 nucleotide index to facilitate error-corrected 
sequencing (Table 5.1). The following conditions were used for amplification: 98C for 30s; 6 
cycles of 98C for 10s, 66C for 30s, 72C for 30s; 72C for 2m; hold 10C. The PCR reaction was 
purified using a modified Ampure bead (Beckman Coulter) cleanup to purify the amplified 
fragments (>400 bp). A modified poly-ethylene glycol (PEG) solution was made containing 
382.5 uL 50% wt/vol PEG (Sigma), and 562.5 uL 5M NaCl and 555 uL ddH2O. 100 uL of beads 
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were washed twice with ddH2O to remove the stock PEG solution. 150 uL of the modified PEG 
solution was added to the washed Ampure beads with the 75 uL PCR reaction and otherwise 
purified using the standard Ampure protocol. The fragments were eluted in 20 uL ddH2O and the 
concentration of each library was quantified with Qubit (Life Technologies).  
4.2.3 Quantification by ddPCR 
Our goal was to generate each error-corrected sequencing (ECS) library from 4M 
uniquely tagged molecules. We quantified each library’s concentration using the QX200 droplet 
digital PCR (ddPCR) platform (Bio-Rad). A 2 uL aliquot of each library was diluted 1000-fold 
and quantified in duplicate wells. Each well contained the following reaction mixture: 10 uL 2x 
EvaGreen 2x ddPCR master mix (Bio-Rad), 5 uL 1:1,000 diluted ECS library, 100 nM P5/P7 
primers (Table 4.1), and ddH2O added to 20 uL total. Droplets were generated using the standard 
Bio-Rad protocol. Amplification was completed using the following conditions: 95C for 5m; 40 
cycles of 95C for 30s, 66C for 1m; 4C for 5m; 90C for 5m; 4C hold. With the calculated 
concentration, we aliquoted the appropriate volume of each library to introduce 4M molecules 
into the subsequent amplification step. 
4.2.4 Amplification and Normalization  
Following ddPCR quantification, 4M molecules for each library were amplified using Q5 
High-Fidelity 2x Master Mix (New England Biolabs) using 1 uM P5/P7 primers (Table 4.1) in a 
50 uL reaction under the following conditions: 98C for 30s; 16 cycles of 98C for 10s, 66C for 
30s, 72C for 30s; 72C for 2m; 4C hold. The PCR reaction was purified using the modified 
Ampure bead cleanup. 100 uL of beads were washed twice with ddH2O and replaced with 100 
uL of the modified PEG solution described above. The PCR reaction was then added to the 
mixture and purified using the standard protocol. The fragments were eluted in 20 uL ddH2O. A 
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2 uL aliquot of each library was diluted 10-fold and quantified on the Agilent 2200 Tape Station. 
Libraries were then pooled in equimolar groups of eight. Once pooled, each library was again 
quantified on the Tape Station and submitted for sequencing.  
4.2.5 Sequencing 
Each library was sequenced on the Illumina NextSeq platform using a 300 cycle high 
output kit as specified by the manufacturer. Approximately 5-10% of PhiX control DNA was 
spiked into each sequencing experiment. Each sequencing run contained roughly 400M paired-
end 144 bp reads with corresponding 16bp unique molecular index (UMI) and 8bp sample-
specific index sequences. Sequenced reads were demultiplexed by sample-specific index 
allowing for at most one mismatch in the index sequence (Table 4.2). Raw sequence reads were 
aligned to the PhiX genome using Bowtie 2159. Sequence reads that did not align to PhiX were 
retained for subsequent analysis (below). 
4.2.6 Error Corrected Sequencing Analysis 
The first 30 nucleotides of each sequenced read were hard clipped to remove the primer 
sequences from the TruSight Myeloid panel. Next, the sequenced read pairs tagged with the 
same random index sequence (originating from the same uniquely tagged DNA molecule) were 
aligned to each other to generate read families in a fashion similar to previously published 
methods117,120,134,135. Read families were required to have five or more reads sharing the same 
index sequence. Paired-end reads within a read family were error corrected to generate an error-
corrected consensus sequence (ECCS) in a stepwise fashion. First, at every position, the 
nucleotides called by each sequence read were compared and a consensus nucleotide was called 
if there was at least 90% agreement between the reads. If there was less than 90% agreement, an 
N was called in the consensus sequence at that position. Errors that occurred during library 
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preparation and sequencing were corrected or removed because they were not shared between 
different reads within a read family. Second, an ECCS was discarded if >10% of the 228 
nucleotides comprising the paired-end read were reported as N nucleotides. ECCSs were then 
locally aligned to UCSC hg19/GRCh37 using Bowtie2 and realigned with GATK’s Indel 
Realigner171.  Next, the aligned ECCSs were processed with Mpileup using the parameters -BQ0 
-d 10000000000000. This removed the coverage thresholds to ensure that all of the pileup output 
was returned regardless of variant allele fraction (VAF) or coverage. The parsed pileup output 
was further filtered to ignore positions with less than 1000x ECCS coverage or outside of the 
Illumina TruSight Myeloid target space. Additionally, germline variants identified by the 1000 
Genomes Project above a 0.01 minor allele fraction were excluded from analysis. 
We implemented a position-specific binomial error model to improve rare clonal single 
nucleotide variants (SNVs) calling as described previously134. For each sample, we generated a 
nucleotide position-specific error profile using all sequenced libraries that were not from the 
same individual. A variant was called if the binomial p-value was: a) less than 0.05 after 
Bonferroni correction, b) the variant was observed in at least 5 ECCSs, c) the VAF was greater 
than 0.0001, and d) the variant was identified with criteria a-c in at least two replicates from one 
of the two time points. Likely clonal SNVs (<0.2 VAF) were reported and annotated using 
Annovar172 with the COSMIC 6837 and 1000 Genomes (Oct 2014 release)173 databases. The 
amino acid substitutions were predicted based on the canonical transcript reported in the 
GENCODE (v22)174 as retrieved from the UCSC Table Browser175.  
We identified potential insertion/deletion (indel) events using VarScan 2176, from the 
filtered Mpileup output (described above), with the following parameters --min-coverage 1000 --
min-reads2  5 --min-var-freq 0.001 --strand-filter 0 --output-vcf 1. We filtered out single 
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nucleotide indels in homopolymer runs at least four nucleotides long and indels that were 
observed in multiple samples to remove technical artifacts in the variant calling. We reported 
likely clonal indels (<0.2 VAF) that were detected in at least two replicates from one of the 
collection time points. Reported indels were annotated with Annovar172 as described previously. 
4.2.7 Droplet Digital PCR Validation 
We validated 21 SNVs and 1 indel using the droplet digital PCR (ddPCR) probe assay 
(Bio-Rad)154. Probes were designed by Bio-Rad based on MIQE guidelines for quantitative 
digital PCR177. All reagents were purchased from Bio-Rad. For each sample and control, 45 ng 
of genomic DNA was aliquoted per well of generated droplets. We generated between 8 and 32 
wells of droplets for each validation experiment, depending on the expected VAF for the assayed 
mutation. Each control sample was assayed with the same number of wells as the corresponding 
sample. Droplets were generated on the QX200 Droplet Generator (Bio-Rad) and assayed on the 
QX200 droplet reader (Bio-Rad) using the standard protocol154. The VAF was estimated from 
droplets lacking the reference allele and the Poisson-estimated number of singleton droplets as 
described previously134.   
4.2.8 Flow cytometry 
Cells were sorted from buffy coat samples using a Sony iCyt Synergy SY3200 BSC 17-
color, 5-laser cell sorter (Sony Biotechnology Inc.) and analyzed with FlowJo (Treestar) using 
standard protocols (Figure 4.1). Cells were stained with the following antibodies (BioLegend): 
CD45 (BV-421), CD33 (APC), CD19 (FITC), CD3 (PE-CY7) per the manufacturer’s 
instructions. Variants were detected in purified cell populations using the ddPCR assay described 
previously. 
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4.2.9 Data Availability 
The sequencing data have been deposited into the NCBI Sequence Read Archive under 
accession number SRP078948. All other relevant data are included in the article or 
supplementary files, or available from the authors upon request. 
4.3 Results 
4.3.1 Variant Quantification in Rare Hematopoietic Clones 
We obtained paired buffy coat blood samples, banked approximately 10 years apart, from 
20 healthy participants in the Nurses’ Health Study (Table 4.3)—a cohort of 121,701 female 
registered nurses longitudinally studied since 1976168–170. The median ages at sample collection 
were 56.6 and 68.1 years old. This facilitated the investigation of benign clonal hematopoiesis in 
younger individuals previously thought to only rarely harbor hematopoietic clones144–147,149. To 
identify hematopoietic clones, we combined ECS with targeted-capture for 568 amplicons in 54 
genes frequently mutated in AML (Methods)117,120,134,135. This enabled us to sequence a tractable 
subset of the genome, while still querying loci associated with clonal hematopoiesis and AML. 
Samples were prepared and sequenced in duplicate. We generated an average of 47.7 million 
paired-end sequencing reads, which yielded an average of 3.4 million error-corrected consensus 
sequences (ECCSs), per library (Table 4.2). 
We modeled position-specific errors in the ECCSs using binomial statistics to identify 
clonal mutations (Methods). We identified 109 clonal single nucleotide variants (SNVs) in at 
least one time point below 0.2 VAF in 95% (19/20) of individuals. We detected 1-17, mostly 
exonic, SNVs per individual at 0.0003-0.1451 (median 0.0024) VAF (Figure 4.2a, Table 4.4). Of 
note, the median VAF we observed was 10-fold less than the detection limit governing previous 
studies of clonal hematopoiesis144–146. Separately, we identified 9 clonal insertion/deletion 
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variants (indels) in 6 individuals (Table 4.5). Indels were identified by ECCS coverage alone, as 
indel errors were not appropriately modeled by the same statistical framework implemented to 
identify SNVs.  
We were initially concerned that most of the identified rare variants were artifacts 
introduced during library preparation or sequencing. We first determined that SNV calls were not 
biased by coverage per amplicon (Figure 4.3) or by the number of bases captured per gene 
(Figure 4.4). Next, we validated these findings using droplet digital PCR (ddPCR)—an 
orthogonal non-sequencing-based technique for VAF quantification. We designed ddPCR assays 
for 21 SNVs that had been previously observed in malignancy37 and for one indel (Figure 4.5). 
The VAFs measured by ECS and ddPCR were highly correlated (R2=0.98, Figure 4.6, Table 
4.6), consistent with the previously observed accuracy of ECS134.  
We next compared the mutation profile observed in these rare hematopoietic clones to 
previous findings in CHIP and AML. We detected 88 exonic clonal SNVs with 58 missense 
SNVs, 17 nonsense SNVs, 9 synonymous SNVs, 3 splicing SNVs, and 1 SNV in a 3’UTR 
(Figure 4.2b). While exonic variants were detected in only 18 of the 54 genes in the panel, 64% 
(56/88) occurred in the epigenetic regulators DNMT3A and TET2 (Figure 4.2c). We frequently 
detected multiple DNMT3A and TET2 mutations in the same individual, which were not 
necessarily in the same clone (Figure 4.7). The DNMT3A SNVs were predominantly nonsense 
mutations in the 5’ end of the gene or missense mutations in the three functional domains (Figure 
4.8). For comparison, TET2 SNVs were primarily missense mutations in the functional domains 
or nonsense mutations throughout the gene (Figure 4.9), consistent with previous observations of 
AML178. While less prevalent, intronic clonal SNVs were observed in 12 genes with 29% (6/21) 
detected in DNMT3A and 5% (1/21) detected in TET2 (Figure 4.10, Figure 4.11). The most 
95 
 
common type of exonic substitution was the cytosine to thymine (C to T) transition (Figure 
4.2d), as previously observed in CHIP144–146. Conversely, intronic SNVs were evenly distributed 
across substitution types.  
4.3.2 Temporal Stability of Rare Clonal Mutations 
We characterized the temporal stability of these clones by tracking clonal mutations 
longitudinally within our 20 study participants. Variants were called independently from paired 
samples banked approximately 10 years apart (Figure 4.12). Of the 109 clonal SNVs identified, 
27.5% (30/109) were detected at both time points, 13.8% (15/109) were detected at only the first 
time point, and 58.7% (64/109) were detected at only the second time point (Table 4.4). The 
stability of VAFs observed here was consistent with previous observations at higher VAFs in a 
few instances of CHIP145. The presence of the same clonal mutations longitudinally suggested 
that these mutations arose in long-lived HSPCs or committed progenitors.  
4.3.3 Clonal Mutations Arise in Hematopoietic Stem and Progenitors 
To further elucidate the cell of origin for clonal hematopoiesis, we sorted 26 samples 
from 13 individuals into B lymphocyte (CD45+CD33-CD19+), T lymphocyte (CD45+CD33-
CD3+) and myeloid (CD45+CD33+) compartments using flow cytometry (Figure 4.1). While 
cell recovery was variable per sample, we observed the same clonal SNVs in both myeloid and 
lymphoid compartments in 10/13 individuals (Figure 4.13, Table 4.7). Frequently, the VAF 
measured in the bulk sample was approximately equal to the VAF measured in each 
compartment. These observations were unlikely to have arisen due to contamination, given that 
variants were often detected at similar VAFs in different sorted compartments.  
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4.4 Discussion 
These findings suggest that clonal hematopoiesis harboring mutations in AML-associated 
genes is nearly ubiquitous (95%) in 50-70 year olds—an age group in which previous studies 
identified hematopoietic clones in only 5% of individuals144–147. Clonal mutations were detected 
in both the myeloid and lymphoid compartments in samples banked a decade apart in these 
healthy individuals, clearly demonstrating that these mutations arose in long-lived HSPCs. 
However, these clonal mutations conferred only a modest proliferation advantage, as most clonal 
mutations were rare (median 0.0024 VAF) and stable longitudinally.  One possible explanation 
for these observations was that these mutations, often in epigenetic regulators, augmented self-
renewal capacity without a concomitant increase in proliferation. This hypothesis may also 
explain why HSPC number increases and quiescence decreases as a function of age179,180. As 
HSPCs gradually senesce throughout life, the acquisition of these mutations may allow benign 
clonal hematopoiesis to maintain ostensibly normal blood production years after it would 
otherwise decline148. This hypothesis is supported by work in mice demonstrating that DNMT3A 
loss-of-function mutations in HSCs are associated with an increase in HSC self-renewal without 
increasing proliferation181. Comparably, TET2 loss-of-function mutations in mice increase HSC 
self-renewal and proliferation182.  
While DNMT3A mutations are frequently observed in CHIP and AML56,144–147, we 
observed a different distribution of DNMT3A mutations, specifically at the arginine 882 (R882) 
residue. Previous studies showed that mutations in DNMT3A R882 comprised approximately 
two-thirds of total DNMT3A mutations in AML45 and one-sixth of DNMT3A mutations in 
CHIP145,146. However, we observed only a single DNMT3A R882H variant. These findings 
suggest that DNMT3A R882 mutations potently drive clonal expansion, explaining their prior 
97 
 
detection in common CHIP clones (median 0.11 VAF)145 and their rarity in these lower 
frequency clones.  
The detection limit of ECS was approximately 1:10,000 cells. Thus, given an estimated 
11,000 hematopoietic stem cells (HSCs) in adults, of which only a fraction actively contribute to 
hematopoiesis at any given time164, we expected to observe unique somatic mutations marking 
each active HSC (a random distribution of synonymous and nonsynonymous mutations 
throughout the 54 AML-associated genes captured). Instead, over half of the detected mutations 
were in DNMT3A or TET2. This observation alone could have occurred if DNMT3A and TET2 
were hotspots of somatic mutation. However, 89% (78/88) of the detected exonic mutations were 
nonsynonymous, truncating or splicing mutations. Given this skew towards presumed functional 
mutations, it was more likely that these hematopoietic clones were enriched by selection. 
Due to technical limitations of our methods, we likely underreported the number of clonal 
mutations present in each individual. Specifically, we likely underreported the number of C to T 
(G to A) substitutions present in these rare hematopoietic clones due to the stringency of the 
binomial variant calling strategy and the background rate of cytosine deamination, which is a 
predominant artifact of error-corrected sequencing117,122,135. Here 38/109 substitutions identified 
were C to T (G to A) substitutions. Conversely, in previous studies of CHIP and AML, C to T (G 
to A) substitutions comprised approximately 50-60% of identified substitutions62,145,146. 
Additionally, the binomial statistical framework underreported hotspot mutations occurring in 
multiple individuals. However, in our raw data we only observed a single likely instance of an 
uncalled hotspot mutation—a DNMT3A R882H variant in individual 5 observed at a lower VAF 
than the variant reported in individual 13. Additionally, we could not routinely co-localize 
mutations within the same hematopoietic clone. However, we co-localized mutations in three 
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instances where they co-occurred in the same sequenced reads (PID 2, TET2 R1216G/A1217A; 
PID 13, DNMT3A G498V/C494F; PID 14, KRAS A66A/S65S).  Future adaptations of this 
technology could address these limitations by targeting a larger capture panel and implementing 
single-cell sequencing approaches.  
In summary, we demonstrate that clonal hematopoiesis, originating in long-lived HSPCs, 
is far more common than previously thought in healthy middle-aged adults. Despite its 
prevalence, clonal hematopoiesis shares many mutations with AML, raising additional questions 
regarding the sequence of mutation acquisition and cooperating events necessary for malignant 
transformation. Furthermore, in previous studies of CHIP the detection of a hematopoietic clone 
(at any age) was associated with an 11-13 fold increased risk of developing a hematological 
malignancy145,146. These earlier findings suggested that CHIP was comparable to monoclonal 
gammopathy of undetermined significance and monoclonal B-cell lymphocytosis, which are 
benign clonal proliferative conditions that occasionally progress to hematological 
malignancy143,149,167. Conversely, our findings suggest that clinically silent clonal hematopoiesis 
is present in almost all individuals by middle age, and that progression to hematological 
malignancy is exceptionally rare. Given the current public interest in precision medicine183, these 
findings have practical implications for sequencing-based screening of nascent malignancy or 
recurrence. Future research must focus on reliably distinguishing benign clonal hematopoiesis, 
however rare, from malignant clonal hematopoiesis that could drive transformation and relapse. 
This imperative extends to sequencing-based non-invasive screening184, which will require even 
finer discrimination between nascent malignancy and benign clonal expansion. 
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Figure 4.1 Representative flow cytometry gating strategy. These results were generated from 
NHS participant 5, time point 1 to isolate B lymphocytes, T lymphocytes and myeloid cells. 
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Figure 4.2 Number and characteristics of clonal SNVs detected by ECS in the peripheral blood 
of healthy adult nurses. a) Clonal SNVs detected in each individual, color-coded by annotation.  
b) Exonic clonal SNVs detected in each individual, color-coded by predicted effect. c) Detected 
exonic clonal SNVs organized by gene, color-coded by predicted effect. d) Distribution of 
substitution types observed in clonal SNVs. 
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Figure 4.3 Coverage per amplicon for error-corrected sequencing experiments. Error-corrected 
consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the 
capture panel. a) Histogram of ECCS coverage for all amplicons. b) Histogram of ECCS 
coverage in amplicons in which a variant was detected. 
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Figure 4.4 Number of mutations detected compared to target space per gene. Mutations detected 
in exons (top panel) and introns (bottom panel) were plotted relative to the capture space (bp = 
base pairs) targeting that gene in the panel.  
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Figure 4.5 Representative droplet digital PCR (ddPCR) results. These results originated from 
NHS participant 12 for the detected DNMT3A G543A clonal variant. The wild-type probe 
intensity in arbitrary units (A.U.) was plotted relative to the DNMT3A G543A (mutant) probe 
intensity for each droplet. a-d) Variant quantification at the first time point for a) all cells; b) B 
lymphocytes; c) T lymphocytes; and d) myeloid cells. e-h) Variant quantification at the second 
time point for e, all cells; f) B lymphocytes; g) T lymphocytes; and h) myeloid cells. i) The 
DNMT3A G543A variant was not detected in the negative control sample from participant 2, 
time point 2. j) Only DNMT3A G543A positive (or empty) droplets were detected in the gblock 
positive control.  
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Figure 4.6 Concordance of variant allele fraction (VAF) measured by error-corrected sequencing 
(ECS) and droplet digital PCR (ddPCR). Several mutations identified by ECS were verified 
using ddPCR. The variant allele fractions (VAFs) identified ECS and ddPCR were highly 
correlated (R2=0.98). 
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Figure 4.7 Heat map depicting the number of exonic single nucleotide variants (SNVs) detected 
in each gene per study participant.  
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Figure 4.8 Detected exonic clonal single nucleotide variants (SNVs) in DNMT3A. The detected 
SNVs were predominantly nonsense mutations (blue) in the first half of the gene or missense 
mutations (red) in the three functional domains—a proline-tryptophan-tryptophan-proline 
(PWWP) chromatin targeting domain, a zinc finger nuclease (ZFN) domain and a S-
adenosylmethionine (SAM) dependent methyltransferase (MTase) domain. 
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Figure 4.9 Detected exonic clonal single nucleotide variants in TET2. 
 
 
  
0 200 400 600 800 1000 1200 1400 1600 1800 2002
4 6 8 10
Oxygenase domain
TET2
L
4
4
6
X
W
9
5
4
X
E
1
1
3
7
_
E
3
s
p
lic
e
R
1
2
1
6
G
A
1
2
1
7
A
G
1
2
8
8
S
F
1
3
0
9
L
Y
1
3
3
7
X
R
1
3
5
9
H
S
1
4
8
6
X
E
1
5
1
3
_
E
1
0
s
p
lic
e
Y
1
5
8
9
X
T
1
7
9
3
I
Silent
Missense
Nonsense
Splice
Exons
AA Residue
109 
 
 
Figure 4.10 Number of intronic clonal single nucleotide variants (SNVs) detected by gene. 
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Figure 4.11 Heat map depicting the number of intronic single nucleotide variants (SNVs) 
detected in each gene per individual. 
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Figure 4.12 Longitudinal detection of clonal SNVs in NHS participants. Clonal SNVs were detected by 
ECS in both time points for 16/20 NHS participants. For each participant ID (PID), the VAF measured by 
ECS was plotted relative to the age at sample collection. Variants detected in both time points were 
connected with a line. 
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Figure 4.13 Hematopoietic compartment-specific detection of clonal SNVs in NHS participants. 
Paired buffy coat samples from 13 individuals were sorted into B lymphocyte (pink), T 
lymphocyte (purple), and myeloid (blue) compartments using flow cytometry. For each NHS 
participant (PID), a single SNV, detected by ECS, was selected for compartment-specific 
quantification by ddPCR. Variants detected in both time points were connected with a line. The 
VAF measured by ddPCR in the bulk sample (green) was included for comparison. 
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Table 4.1 Primer sequences for library preparation. 
 
Primer 
Name Sequence 
i5 16N 
Random 
AATGATACGGCGACCACCGAGATCTACACNNNNNNNNNNNNNNNNACACTCTT
TCCCTACACGACGCTCTTCCGATCT 
P5 AATGATACGGCGACCACCGA 
P7 CAAGCAGAAGACGGCATACGA 
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Table 4.2 Sequenced reads and error-corrected consensus sequences (ECCS) generated for each 
library. 
 
 
Collection 1 Replicate 1 Collection 1 Replicate 2 Collection 2 Replicate 1 Collection 2 Replicate 2 
PID Raw Reads ECCS Raw Reads ECCS Raw Reads ECCS Raw Reads ECCS 
1 38,483,255 3,333,626 33,448,218 2,804,567 35,427,539 2,987,274 33,392,978 2,784,229 
2 39,268,072 3,318,173 41,984,812 3,558,516 35,157,811 3,027,607 33,657,209 2,860,180 
3 32,603,819 2,581,039 36,107,671 2,959,152 48,998,142 3,584,046 40,599,238 3,291,215 
4 30,932,163 2,212,764 30,623,846 2,501,632 39,579,433 3,254,544 48,529,452 3,503,765 
5 35,011,143 2,727,030 34,151,207 2,411,821 52,302,285 3,759,106 55,049,072 4,017,037 
6 34,207,169 2,863,690 35,084,657 2,946,669 50,852,817 3,682,303 48,351,486 3,514,019 
7 41,658,678 2,663,917 42,508,068 2,714,869 45,885,262 3,233,300 44,468,353 3,548,708 
8 44,771,597 2,734,288 41,632,517 2,528,357 50,072,031 3,399,553 50,378,471 3,698,270 
9 39,449,116 2,531,229 41,067,140 2,599,127 60,014,462 4,197,532 50,347,145 3,993,077 
10 40,492,765 2,554,060 38,729,489 2,400,500 59,870,612 4,034,423 58,962,293 3,996,550 
11 48,940,303 3,684,038 44,034,692 3,456,949 64,520,183 4,096,893 56,501,287 3,797,404 
12 57,115,177 4,245,185 48,446,875 3,692,857 61,813,583 4,322,748 59,452,070 4,110,288 
13 39,368,839 3,059,660 41,269,631 3,343,408 59,327,495 4,213,628 52,689,305 4,173,008 
14 38,837,743 3,076,601 37,306,017 2,976,419 60,366,370 4,053,326 58,109,532 4,501,213 
15 54,605,075 3,407,283 44,547,457 2,490,226 58,101,101 3,908,542 51,539,869 4,104,014 
16 52,226,742 2,986,829 60,744,391 3,907,372 45,532,881 3,414,608 60,632,143 4,027,633 
17 57,985,852 4,079,429 51,835,232 3,373,746 55,355,241 3,721,052 59,501,527 4,096,858 
18 54,185,217 3,337,380 54,495,083 3,388,504 57,117,288 4,147,180 58,064,485 3,999,074 
19 52,213,946 2,947,031 51,028,264 3,343,682 53,983,868 3,723,161 48,268,843 3,796,565 
20 51,521,626 3,376,026 41,417,619 2,806,990 58,651,106 4,092,482 56,692,728 3,793,691 
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Table 4.3 Age at sample collection for each NHS participant. 
 
Participant 
ID 
Collection 1 
Age 
Collection 2 
Age 
1 53.5 64.6 
2 51.2 63.0 
3 52.3 64.4 
4 53.4 64.2 
5 52.2 64.4 
6 57.9 69.2 
7 60.1 71.4 
8 56.5 68.5 
9 58.0 69.0 
10 54.7 66.9 
11 63.5 74.5 
12 56.4 67.3 
13 56.6 68.5 
14 60.1 71.8 
15 57.6 67.7 
16 54.1 65.4 
17 51.7 63.1 
18 65.1 76.2 
19 64.0 75.1 
20 62.8 74.6 
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Table 4.4 Clonal SNVs detected by error-corrected sequencing. 
 
PID Chr Pos Ref Alt Gene AA Change COSMIC VAF1.1 VAF1.2 VAF2.1 VAF2.2 
1 7 50444517 T C IKZF1 intronic   0.0009 - 0.0010 0.0029 
1 X 123185174 G T STAG2 V376L   0.0028 0.0012 0.0180 0.0170 
2 2 25463271 G T DNMT3A A741E   0.0011 - 0.0010 0.0010 
2 2 25463277 T G DNMT3A H739P   0.0017 0.0003 0.0004 0.0005 
2 2 25466793 A G DNMT3A L637P   0.0014 0.0034 0.0035 0.0056 
2 2 25468153 A G DNMT3A L508P   - 0.0012 0.0076 0.0085 
2 2 25470573 G A DNMT3A R301W   - - 0.0026 0.0035 
2 4 106164778 C G TET2 R1216G   - - 0.0011 0.0010 
2 4 106164783 T A TET2 A1217A   - - 0.0011 0.0010 
2 12 11803160 G C ETV6 intronic   0.0012 0.0006 - - 
4 2 25470516 G A DNMT3A R320X 133724 0.0036 0.0036 0.0052 0.0026 
4 9 139391179 G A NOTCH1 Q2338X   0.0011 0.0010 - - 
4 X 123184056 G T STAG2 R305L 254953 0.0091 0.0078 0.0149 0.0185 
5 2 25466799 C T DNMT3A R635Q 1583088 - - 0.0015 0.0027 
6 2 25471183 C G DNMT3A intronic   0.0016 0.0015 - - 
6 3 38181952 C T MYD88 I192I   - - 0.0018 0.0016 
6 4 106180899 T G TET2 F1309L   0.0014 0.0013 0.0009 0.0008 
6 7 101843537 T G CUX1 intronic   0.0040 0.0042 0.0017 0.0052 
6 11 119148929 A G CBL I383M   0.0014 0.0004 - - 
7 2 25457176 G A DNMT3A P904L 87007 0.0024 - 0.0085 0.0104 
7 2 25458673 T C DNMT3A T834A   0.0029 0.0035 0.0026 0.0040 
7 2 25462012 G A DNMT3A P799S   - - 0.0023 0.0048 
7 2 25463372 G A DNMT3A intronic   0.0042 0.0039 0.0034 - 
7 2 25463384 G A DNMT3A intronic   0.0066 0.0082 0.0029 - 
7 2 25463385 C G DNMT3A intronic   - - 0.0066 0.0087 
7 2 25463387 C G DNMT3A intronic   0.0067 0.0079 0.0032 - 
7 2 25463389 G A DNMT3A intronic   0.0068 0.0077 0.0038 - 
7 2 25464441 G A DNMT3A T691I   - - 0.0036 0.0025 
7 2 25464514 C A DNMT3A E667X   - - 0.0011 0.0032 
7 2 25466788 G A DNMT3A L639F   0.0216 0.0206 0.0407 0.0295 
7 2 25467449 C T DNMT3A G543S   - - 0.0048 0.0033 
7 4 106158509 G A TET2 splicing 87117 - - 0.0010 0.0015 
7 4 153249632 T C FBXW7 intronic   0.0004 0.0003 - - 
7 7 50367256 C T IKZF1 S21S   0.0035 0.0041 0.0021 - 
7 X 76874262 A T ATRX intronic   - - 0.0005 0.0003 
7 X 123199914 G T STAG2 intronic   - - 0.0008 0.0009 
8 2 25468919 C A DNMT3A E482X   - - 0.0031 0.0040 
8 4 106180834 G A TET2 G1288S 110780 0.0012 0.0024 0.0020 0.0011 
9 2 25459821 T C DNMT3A H821R   - 0.0022 0.0017 0.0025 
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PID Chr Pos Ref Alt Gene AA Change COSMIC VAF1.1 VAF1.2 VAF2.1 VAF2.2 
9 2 25462086 T C DNMT3A splicing   0.0026 - 0.0015 0.0015 
9 2 25463247 C T DNMT3A R749H   0.0203 0.0177 0.0333 0.0356 
9 2 25463541 G C DNMT3A S714C 87011 0.0273 0.0303 0.0412 0.0341 
9 2 25466800 G A DNMT3A R635W 87012 0.0019 0.0036 - 0.0012 
9 2 25467160 G T DNMT3A A572D   - - 0.0010 0.0021 
9 2 25469632 C T DNMT3A R379H   - - 0.0029 0.0057 
9 2 25470588 C T DNMT3A V296M   - - 0.0035 0.0032 
9 2 25471016 G A DNMT3A Q249X   0.0014 - 0.0013 0.0013 
9 4 106193995 C G TET2 S1486X 211625 - - 0.0005 0.0006 
9 20 31023091 A G ASXL1 N859S   0.0041 0.0029 0.0044 0.0032 
9 X 44733267 T G KDM6A intronic   - - 0.0017 0.0013 
10 12 25380459 G C KRAS intronic   - - 0.0010 0.0009 
10 X 129162659 C G BCORL1 H1376Q   0.0049 0.0023 0.0018 - 
11 2 25458595 A G DNMT3A W860R 231568 0.0009 0.0015 0.0020 0.0025 
11 2 25470914 C A DNMT3A E283X   0.0042 0.0056 0.0129 0.0143 
11 2 25505372 G C DNMT3A S129X   - - 0.0007 0.0005 
11 3 38182245 T A MYD88 intronic   - - 0.0019 0.0022 
11 17 7577129 A G TP53 F270S 11305 - - 0.0007 0.0016 
11 20 31023606 A T ASXL1 K1031X   0.0007 0.0008 - - 
11 X 39933358 G A BCOR A414V   - - 0.0006 0.0009 
11 X 44733249 G T KDM6A intronic   - - 0.0009 0.0008 
11 X 76814150 A T ATRX F2165Y   0.0007 0.0007 - - 
11 X 129148158 A G BCORL1 L470L   - - 0.0003 0.0005 
12 2 25467448 C G DNMT3A G543A 256033 0.0014 - 0.0038 0.0039 
12 4 106155048 C G TET2 intronic   - - 0.0010 0.0020 
12 10 112342324 C T SMC3 S243F   - - 0.0014 0.0018 
13 2 25457192 G C DNMT3A R899G   0.0025 0.0015 0.0013 0.0018 
13 2 25457242 C T DNMT3A R882H 52944 - - 0.0018 0.0017 
13 2 25458658 A G DNMT3A S839P   0.0003 - 0.0011 0.0006 
13 2 25463298 A G DNMT3A F732S   0.0015 - 0.0030 0.0032 
13 2 25467466 C A DNMT3A C537F   - - 0.0019 0.0034 
13 2 25468183 C A DNMT3A G498V   0.0009 - 0.0037 0.0060 
13 2 25468195 C A DNMT3A C494F   0.0009 - 0.0037 0.0060 
13 2 25470532 C T DNMT3A W314X   - - 0.0021 0.0026 
13 2 25470570 C A DNMT3A G302C   - - 0.0016 0.0010 
13 8 117859842 T C RAD21 Y598C   - - 0.0005 0.0006 
14 2 25470464 G C DNMT3A S337X   0.0252 0.0240 0.0423 0.0448 
14 12 25380260 T G KRAS A66A   - - 0.0063 0.0055 
14 12 25380263 A G KRAS S65S   - - 0.0064 0.0056 
14 X 44911015 C T KDM6A A239V   - - 0.0043 0.0056 
15 2 25458670 T C DNMT3A T835A   - - 0.0005 0.0005 
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PID Chr Pos Ref Alt Gene AA Change COSMIC VAF1.1 VAF1.2 VAF2.1 VAF2.2 
15 10 112342321 T C SMC3 L242P   0.0028 0.0034 0.0036 0.0047 
15 17 7577105 G T TP53 P278H 43755 0.0162 0.0163 0.0317 0.0395 
15 20 31024085 G T ASXL1 R1190S   - - 0.0011 0.0005 
15 X 123234540 T A STAG2 UTR3   - - 0.0007 0.0006 
16 2 25463568 A G DNMT3A I705T 1583102 0.0663 0.0788 0.0457 0.0582 
17 2 25463301 A G DNMT3A F731S   0.0012 - 0.0019 0.0026 
17 4 106156436 T G TET2 L446X   - - 0.0007 0.0009 
17 4 106197045 C T TET2 T1793I   - - 0.0013 0.0019 
17 X 39932643 G A BCOR P652P   0.0055 0.0058 0.0019 0.0029 
17 X 123224536 A T STAG2 K1130I   0.0008 0.0009 0.0009 0.0010 
17 X 129173203 G A BCORL1 G1522S   - - 0.0004 0.0004 
18 2 25471070 G A DNMT3A Q231X   0.0015 0.0014 0.0019 0.0009 
18 4 106157961 G A TET2 W954X 87110 - - 0.0023 0.0009 
18 4 106182972 T A TET2 Y1337X 87145 - - 0.0015 0.0013 
18 7 101840496 G A CUX1 R602H   0.1479 0.1424 0.0828 0.0693 
18 7 148515272 A G EZH2 intronic   - - 0.0013 0.0013 
18 X 44938634 A G KDM6A intronic   0.0138 0.0121 0.0146 0.0137 
18 X 129149098 C T BCORL1 R784X 1319521 - - 0.0186 0.0173 
19 4 106196434 T G TET2 Y1589X   - 0.0021 0.0023 0.0025 
19 11 119148922 G A CBL C381Y 34073 0.0010 0.0014 0.0011 0.0018 
19 17 7578427 T C TP53 H168R 43545 0.0007 0.0010 0.0033 0.0032 
19 X 76813170 A G ATRX intronic   - - 0.0007 0.0010 
19 X 123179344 C T STAG2 intronic   0.0190 0.0160 0.0202 0.0222 
20 2 25505559 T C DNMT3A K67E   0.0052 0.0080 0.0076 0.0100 
20 4 106190798 G A TET2 R1359H   0.0035 0.0032 - - 
20 4 106194076 G A TET2 splicing   - - 0.0015 0.0017 
20 8 117878873 C A RAD21 V32V   0.0043 0.0040 0.0075 0.0071 
20 12 12022854 C A ETV6 V320V   - - 0.0010 0.0016 
20 12 25398284 C T KRAS G12D 521 - - 0.0009 0.0014 
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Table 4.5 Clonal insertion/deletion variants detected by error-corrected sequencing. We reported 
the variant allele fraction (VAF) for each variant detected in two replicates from at least one of 
the two time points. 
 
PID Chr Start End Ref Alt Gene AA VAF1.1 VAF1.2 VAF2.1 VAF2.2 
7 2 25463381 25463381 - GTG DNMT3A intronic 0.0068 0.0070 0.0030 - 
7 4 106155858 106155861 CAGT - TET2 N253fs 0.0063 0.0063 0.0133 0.0126 
7 4 106164895 106164895 - A TET2 
Y1255_G1
256delinsX 
0.0072 0.0052 0.0074 0.0090 
9 2 25463567 25463567 A - DNMT3A I705fs 0.0331 0.0229 0.0601 0.0801 
9 2 25467528 25467547 
AGCAG
CGGGA
AGGGT
CAGAA 
- DNMT3A intronic - - 0.0038 0.0041 
11 2 25468168 25468168 - T DNMT3A T503fs - - 0.0030 0.0031 
15 8 117862892 117862895 TCTC - RAD21 E528fs 0.0068 0.0065 0.0142 0.0128 
18 X 123179310 123179318 
ATTAAT
TTT 
- STAG2 intronic 0.0277 0.0255 0.1193 0.1207 
20 4 106190864 106190864 C - TET2 A1381fs 0.0052 0.0032 0.0400 0.0256 
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Table 4.6 Summary of droplet digital PCR validation experiments. The variant allele fraction 
(VAF) determined by error-corrected sequencing (ECS) was included for comparison. For each 
experiment, a control sample was selected where the variant of interest was not observed in the 
ECS data. For the control samples, the same number of genome equivalents were analyzed as the 
experimental sample.  
 
PID Gene AA 
ECS 
VAF 
1.1 
ECS 
VAF 
1.2 
ddPCR 
VAF 1 
ECS 
VAF 2.1 
ECS 
VAF 2.2 
ddPCR 
VAF 2 
Control 
Control 
VAF 
4 DNMT3A R320X 0.0036 0.0036 0.0068 0.0052 0.0026 0.0063 1.2 0.0000 
4 STAG2 R305L 0.0091 0.0078 0.0101 0.0149 0.0185 0.0176 1.1 0.0000 
5 DNMT3A R635Q - - 0.0009 0.0015 0.0027 0.0020 15.1 0.0000 
7 DNMT3A P904L 0.0024 - 0.0020 0.0085 0.0104 0.0088 3.1 0.0000 
7 TET2 splice - - 0.0009 0.0010 0.0015 0.0014 3.2 0.0000 
8 TET2 G1288S 0.0012 0.0024 0.0017 0.0020 0.0011 0.0016 2.1 0.0000 
9 DNMT3A S714C 0.0273 0.0303 0.0282 0.0412 0.0341 0.0385 2.2 0.0000 
9 DNMT3A R635W 0.0019 0.0036 0.0035 - 0.0012 0.0020 10.2 0.0000 
9 TET2 S1486X - - - 0.0005 0.0006 0.0004 6.1 0.0000 
11 TP53 F270S - - 0.0005 0.0007 0.0016 0.0006 2.1 0.0000 
11 DNMT3A W860R 0.0009 0.0015 0.0007 0.0020 0.0025 0.0022 6.2 0.0000 
12 DNMT3A G543A 0.0014 - 0.0007 0.0038 0.0039 0.0027 2.2 0.0000 
13 DNMT3A R882H - - 0.0002 0.0018 0.0017 0.0020 14.1 0.0000 
15 TP53 P278H 0.0162 0.0163 0.0143 0.0317 0.0395 0.0378 10.2 0.0001 
16 DNMT3A I705T 0.0663 0.0788 0.0753 0.0457 0.0582 0.0545 14.1 0.0000 
18 TET2 W954X - - 0.0002 0.0023 0.0009 0.0012 10.1 0.0000 
18 TET2 Y1337X - - 0.0000 0.0015 0.0013 0.0012 6.1 0.0000 
18 BCORL1 R784X - - 0.0031 0.0186 0.0173 0.0171 14.2 0.0000 
19 CBL C381Y 0.0010 0.0014 0.0010 0.0011 0.0018 0.0013 17.2 0.0000 
19 TP53 H168R 0.0007 0.0010 0.0008 0.0033 0.0032 0.0029 6.2 0.0000 
20 KRAS G12D - - 0.0001 0.0009 0.0014 0.0010 17.1 0.0000 
20 TET2 A1381fs 0.0052 0.0032 0.0035 0.0400 0.0256 0.0357 13.1 0.0000 
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Table 4.7 Summary of variant allele fractions (VAF) detected by droplet digital PCR in sorted 
hematopoietic compartments.  
 
PID Gene AA COSMIC Collection Bulk B T M 
4 DNMT3A R320X 133724 1 0.0068 0.0048 0.0005 0.0019 
    
2 0.0063 0.0063 0.0012 0.0039 
5 DNMT3A R635Q 1583088 1 0.0009 0.0006 0.0005 0.0005 
        2 0.0020 0.0020 0.0015 0.0018 
7 DNMT3A P904L 87007 1 0.0020 0.0025 0.0001 0.0009 
    
2 0.0088 0.0135 0.0018 0.0037 
8 TET2 G1288S 110780 1 0.0017 0.0000 0.0000 0.0006 
        2 0.0016 0.0000 0.0000 0.0001 
9 DNMT3A S714C 87011 1 0.0282 0.0060 0.0018 0.0028 
    
2 0.0385 0.0066 0.0044 0.0058 
11 DNMT3A W860R 231568 1 0.0007 0.0000 0.0000 0.0001 
        2 0.0022 0.0000 0.0000 0.0019 
12 DNMT3A G543A 256033 1 0.0007 0.0000 0.0043 0.0048 
    
2 0.0027 0.0015 0.0123 0.0121 
13 DNMT3A R882H 52944 1 0.0002 0.0000 0.0000 0.0001 
        2 0.0020 0.0018 0.0000 0.0002 
15 TP53 P278H 43755 1 0.0143 0.0234 0.0046 0.0035 
    
2 0.0378 0.0231 0.0358 0.0084 
16 DNMT3A I705T 1583102 1 0.0753 0.0760 0.0084 0.0350 
        2 0.0545 0.0701 0.0218 0.0408 
18 TET2 W954X 87110 1 0.0002 0.0000 0.0000 0.0000 
    
2 0.0012 0.0033 0.0004 0.0003 
19 TP53 H168R 43545 1 0.0008 0.0007 0.0000 0.0000 
        2 0.0029 0.0027 0.0006 0.0000 
20 KRAS G12D 521 1 0.0001 0.0000 0.0002 0.0007 
    
2 0.0010 0.0037 0.0001 0.0036 
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Chapter 5: Discussion 
5.1 Change 
Change is the only constant in genomics. Every day as our cells divide, differentiate and 
replenish our body, the underlying genomic blueprint of each cell changes. Every cell division 
propagates these new genetic and epigenetic modifications. Fortunately, the genome is large and 
most of these changes are inconsequential. Now the technology exists to deeply study these 
genomic changes within an organism. Change is also a central tenet of the sequencing 
technology that drives our growing understanding of genomics. During the Sanger-sequencing 
era, the cost of sequencing decreased yearly at a rate paralleling Moore’s Law, culminating in the 
three billion dollar effort to sequencing the first human genome22,185,186. Since the development 
of NGS, sequencing costs have decreased even more rapidly and a human genome can now be 
sequenced for approximately one thousand dollars185. This democratization of sequencing has 
fostered a genomics renaissance illuminating the fundamentals of life and evolution. Ironically, 
this explosion of knowledge did not immediately provide cures for the panoply of human 
ailments. Instead, it exposed the vast complexity of human biology and malignancy. Regardless, 
the foundation of knowledge is growing and slowly being translated into targeted therapeutics, 
sensitive diagnostic and screening tools, and novel immunotherapies. It is exciting to imagine 
how future advancements will enhance this knowledge and improve treatment for patients 
battling cancer. 
Here, we developed novel experimental and computational methods to improve rare 
variant detection with standard NGS technology. We characterized previously undetectable rare 
clonal populations in pre-chemotherapy blood and bone marrow samples from individuals who 
later developed t-AML/t-MDS and in the peripheral blood of healthy individuals. We were the 
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first to describe the ubiquitous presence of rare hematopoietic clones harboring leukemia-
associated mutations in healthy individuals. While these were interesting findings, it is exciting 
to look forward and wonder when this cutting edge technology will become obsolete. While the 
cost of sequencing has dramatically decreased over the past decade, the accuracy of sequencing 
has not significantly improved. We were able to circumvent the NGS error rate using our 
methods for ECS. However, future advancements in this field must improve sequencing 
accuracy, throughput and seamless integration with single-cell techniques. 
5.2 Future Exploration in Clonal Hematopoiesis 
Presented here is the first application of targeted-ECS to study clonal hematopoiesis in 
healthy middle-aged individuals. However, the causes and effects of clonal hematopoiesis are 
still not well understood. Given our current understanding of leukemogenesis and the age-
dependent increase in risk of leukemia, we hypothesize that clonal expansion rarely occurs in 
younger individuals. To directly answer this question, we designed a study using targeted-ECS to 
identify rare hematopoietic clones in cord blood samples. The capture panel for this study was 
expanded to include genes recurrently mutated in pediatric AML. Future work could expand the 
study to include samples collected in adolescence and young adulthood. While difficult to obtain, 
longitudinal studies of healthy individuals are essential to understand the stability of these 
hematopoietic clones over time. Additionally, similar studies in individuals with germline 
mutations in cancer predisposition genes would help describe the transition from benign clonal 
hematopoiesis to fulminant leukemia187. These studies would be well suited to unveil the discrete 
steps that transform benign clonal expansion into a founding leukemic clone.  
Another feasible study, given the current ECS technology, is the examination of rare 
clones in different hematopoietic compartments. Using flow cytometry, we were able to detect 
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rare clonal mutations in both myeloid and lymphoid cells. Thus, these clonal mutations most 
likely arose in hematopoietic stem and progenitor cells (HSPCs). However, the functional effect 
of these leukemia-associated mutations in HSPCs is largely unknown. Previous work in mice 
demonstrated that loss-of-function mutations in DNMT3A resulted in increased hematopoietic 
stem cell (HSC) self-renewal, but not proliferation181. In a separate study, TET2 loss-of-function 
mutations increased HSC self-renewal and proliferation182. Now the technology exists to 
examine the characteristics of clonal HSPC expansion in healthy adults who spontaneously 
acquire these mutations, but do not acquire leukemia. Future work could quantify compartment-
specific expansion and skewing during differentiation. In this type of study, clonal mutations that 
block differentiation would appear as clonal expansion in a specific progenitor population. 
So far, these proposed studies would examine the cell intrinsic characteristics of 
leukemia-associated mutations on clonal expansion. However, HSPCs do not exist in isolation 
from their environment. Instead there is a rich milieu of cytokines, circulating hematopoietic 
cells and the bone marrow niche that directly modulate the quiescence and activity of HSPCs. 
The interplay of these extrinsic factors and HSPCs harboring leukemia-associated mutations is 
totally unknown. One puzzling observation from our study of clonal hematopoiesis in healthy 
individuals was the spectrum of somatic mutations. Given the sensitivity of our technology and 
the estimated number of HSCs in humans, we expected to observe a random pattern of mutations 
mirroring the rate of somatic mutation and genetic drift in individual HSPCs. Instead, two-thirds 
of the observed mutations were in the epigenetic modifiers DNMT3A and TET2, suggesting that 
selection was already acting to enrich these clonal mutations that were in as few as 1:10,000 
peripheral blood cells. Understanding the source of this selection could potentially explain why 
human HSCs increase in frequency, become more myeloid biased and decrease quiescence as a 
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function of age179. It is possible that these two phenomenon are related. Perhaps a lifetime of 
infections, inflammatory processes and environmental exposures select for HSPCs that acquired 
these mutations in epigenetic modifiers. As a consequence, an oligoclonal marrow harboring 
leukemia-associated mutations may be necessary to maintain ostensibly normal blood production 
late in life. Using standard flow sorting techniques and ECS, it is currently possible to study the 
effect of inflammation and infection on clonal selection in the hematopoietic compartment.  
5.3 Residual disease detection in AML with ECS 
Current work in the lab will produce the first comparison of targeted-ECS to 
multiparameter flow cytometry (MPFC) for residual disease detection in AML. This 
collaboration with the Children’s Oncology Group will enable us to test ECS-based residual 
disease detection in a large cohort of pediatric AML cases. There are several possible outcomes 
from this study. One outcome is that detected leukemic clones or subclones persist following 
treatment and predict a poor outcome. Alternatively, pre-leukemic clones harboring a subset of 
the leukemia-associated mutations may predominate post-induction, repopulate the marrow, and 
reconstitute an ostensibly normal hematopoietic compartment. Yet another possibility, therapy 
may select for a clonal population unrelated to the leukemia that expands post-induction. 
Regardless, this study will explore the characteristics of clonal expansion and mutation clearance 
post-induction that predict patient outcomes. Already, in adult AML the clearance of all 
leukemia-associated mutations to a detection limit of 0.025 variant allele fraction (VAF) was 
associated with better event-free survival and overall survival111. However, 70% of individuals 
who cleared all of their mutations at that limit of detection relapsed by 40 months. Using ECS, 
the limit of detection for clonal mutations is much lower. Likewise, this study will determine if 
mutation clearance at a lower limit of detection corresponds with longer event free survivals. 
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Complicating this analysis is the observation that non-leukemic hematopoietic clones expand 
following induction therapy in adult AML112. While a challenging task, future work will help 
discriminate between benign clonal expansion following treatment and malignant clonal 
expansion that precedes relapse. 
5.4 Clonal evolution in solid organs 
The hematopoietic compartment is the ideal system to study clonal evolution for a variety 
of reasons. Samples are routinely acquired from healthy individuals and often serially banked 
during the natural history of hematological disease. Conversely, it is difficult to study clonal 
evolution in solid organs. Focusing on malignancy, two pioneering studies described the 
exquisite geographical diversity of clonal mutations in renal cell carcinoma and pancreatic 
cancer60,61. However, a similar study of benign clonal expansion in a disease-free kidney or 
pancreas is not feasible. The only sequencing-based clonal evolution study of a solid organ 
characterized somatic mutations in eyelid epidermis, one of the only disease-free tissues 
routinely removed from healthy individuals188. Interestingly, they observed a high burden of 
somatic mutations, similar to many cases of skin cancer, that reflected the spectrum of mutations 
introduced by UV light. It would be fascinating to explore clonal evolution in other organ 
systems that do not experience the same level of DNA damage as sun-exposed skin. Studying 
somatic mutation acquisition and clonal evolution in a variety of organ systems would help 
clarify the effect of “bad luck”—spontaneous random mutations arising in disease-free stem 
cells—on the organ-specific risk of developing malignancy189. Regardless, the characterization 
of rare clonal expansion in non-hematopoietic organ systems is an important and necessary 
undertaking in order to understand the process of malignant transformation. 
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5.5 Predicting solid tumor development and relapse with 
circulating cell-free DNA 
One challenge when treating solid malignancies is the accurate assessment of response to 
treatment and risk of relapse. While neoadjuvant chemotherapy and surgery can often effectively 
remove the primary tumor, distant metastases often escape therapy and may spawn recurrence. 
Currently, response to treatment is measured with the Response Evaluation Criteria in Solid 
Tumours (RECIST) criteria, which assesses disease burden using imaging modalities such as X-
ray computed tomography (CT) and fluorodeoxyglucose-positron emission tomography (FDG-
PET)190,191. Unfortunately, these methods are insensitive to detect occult lesions that frequently 
seed relapse. Interestingly, circulating tumor cells (CTCs) have been detected in the blood of 
individuals with metastatic breast cancer, prostate cancer, colorectal cancer, and a variety of 
other carcinomas192–194. Detecting as few as five CTCs per 7.5 mL vial of whole blood was 
associated with shorter progression free survival and lower overall survival. This method 
routinely detected residual malignant cells that were invisible using imaging modalities. 
However, by targeting epithelial cell surface markers, these methods miss many malignant cells 
such as tumor stem cells and CTCs that have undergone epithelial to mesenchymal transition195. 
These methods have improved over the years, but the primary challenge will always concern the 
identification of a sensitive and specific cell surface marker of disease.  
More recent advancements circumvent this limitation by targeting the genomic DNA 
from malignant cells directly in the circulating cell-free fraction of the peripheral blood 
(cfDNA)196. In an early study of a few cases of metastatic breast cancer, tumor-specific 
mutations were detected in cfDNA and correlated with disease course197. More recent studies 
have utilized targeted sequencing of cancer-associated hot spots and whole genome sequencing 
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to identify malignancy-associated mutations in cfDNA156,198. Interestingly, these methods could 
detect malignancy-associated mutations not observed in the primary tumor. While these methods 
were sensitive to detect malignancy-associated somatic mutations, the prognostic value of 
mutation burden in the cfDNA is still largely unknown. While the relative abundance of tumor-
specific cfDNA may not directly correlate with disease burden or risk of disease progression, the 
absence of tumor-specific cell-free DNA may reflect disease clearance. Likewise, a binary 
readout of tumor DNA burden may be the most efficacious application of cfDNA sequencing. In 
that case, detecting rare tumor-specific mutations will be a critical component of disease 
assessment. Our ECS methods could improve the limit of detection for these rare malignancy-
associated somatic mutations in cfDNA. While proposed, ECS has not yet been applied to rare 
tumor-associated mutations detection in cfDNA196. These proposed studies focus on cfDNA in 
peripheral blood; however, any medium is suitable for detecting the genomic signature of occult 
disease. One pioneering study retrospectively identified cases of ovarian and endometrial cancer 
by identifying tumor-specific mutations in Papanicolaou (Pap) smear samples using targeted-
ECS127. In general, there is great potential for the application of ECS to quantify response to 
treatment for solid malignancies. 
Another exciting application of cfDNA analysis is for the identification of malignancy 
before clinical presentation. Currently, only the sequencing company Illumina is pursuing this 
goal with the creation of a separate entity, Grail. This is a high risk venture for several reasons. 
First, the amount of sequencing required per person is nontrivial. Tumor-specific cfDNA will 
likely make up only a small portion of the total cfDNA and will only be detectable with ECS. 
Additionally, the target-space for capture must be large to recover a broad set of driver mutations 
across multiple cancer types. Second, the relationship between detecting malignancy-associated 
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mutations in cfDNA and the development of cancer are totally unknown. While initially 
optimistic about this venture, our study of clonal hematopoiesis in healthy individuals 
demonstrated that virtually all healthy individuals have detectable leukemia-associated somatic 
mutations in their peripheral blood by late adulthood. The shear breadth of sequencing and low 
limit of detection will invariably lead to the detection of benign clonal expansions and rare 
mosaic populations in healthy individuals. The discrimination between these benign processes 
and actionable pre-clinical malignant disease will be a monumental challenge.  
5.6 Leveraging improvements in sequencing technology to 
study clonal evolution 
Now, we are on the cusp of several advancements in sequencing technology. It is exciting 
and humbling to think that our cutting edge ECS technology will likely be obsolete in only a few 
years. It will be exciting to how improving this fundamental tool will enable future studies of 
clonal evolution and the development of malignancy. Two emerging technologies are Single-
Molecule Real-Time (SMRT) sequencing and nanopore sequencing. The two major limitations 
of NGS are that sequenced reads are short (300-600 bp long) and the error-rate is approximately 
1%. While we can circumvent the error rate with ECS, the short reads are an intrinsic limitation 
of NGS. Conversely, SMRT sequencing can generate much longer reads (>1,000 bp long), but 
have a high error rate (up to 14%)199. This technology works by observing replication of a single 
DNA strand in a restricted space called a zero-mode waveguide. So far, this technology has been 
instrumental in genome assembly, which is nearly impossible in repetitive regions using short 
NGS-generated reads200. Likewise, these long reads have improved structural variant mapping in 
the human genome201. Nanopore sequencing generates long sequence reads by monitoring 
changes in ionic current as a DNA molecule passes through a membrane-bound nanopore202. 
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While these long nanopore-generated reads also have a high intrinsic error rate, their 
combination with NGS-reads and statistical modelling have generated accurate genome 
assemblies203,204. More recent advancements allowed polarity reversal in individual pores to 
reject molecules that have already been sequenced205. Together these technologies are currently 
well suited for de novo genome assembly and structural variant identification. 
While a fascinating group of technologies, currently, they are ill-suited for rare variant 
detection. If future versions of these technologies can achieve an error-rate similar ECS, then this 
tool will enable key experiments regarding clonal evolution. Specifically, this tool would enable 
the phasing of mutations occurring in the same gene and the reliable detection of rare clonal 
translocations and rearrangements. It is not farfetched to envision a future technology, which 
could phase mutations along an entire chromosome. However, those advancements may be a 
way off. Even if current nanopore technology could sequence an entire chromosome, it would 
take 41 days at 70bp/s to read chromosome 1, which is 249 million bp long205. Despite these 
hypothetical applications for long-read sequencing, their development alone will not likely 
dramatically improve our understanding of clonal evolution and malignant transformation. 
However, combining these technologies with future advancements in single-cell partitioning and 
sequencing will revolutionize our understanding of malignancy, clonal evolution and 
fundamental cellular biology.  
5.7 Future applications of single-cell sequencing. 
Single-cell sequencing technologies are rapidly improving. Already, single-cell RNA 
sequencing approaches can tag transcripts from individual cells and distinguish cell types based 
on commonly expressed transcripts206. Single-cell genomic DNA sequencing approaches enabled 
the identification of the clonal architecture within a few cases of pediatric ALL79. This approach 
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queried individual loci, identified by bulk sequencing at diagnosis, to uncover the clonal 
architecture and infer the clonal evolution of these tumors. More recent advancements leverage 
microfluidic partitioning of genomic DNA to phase and haplotype inherited germline variants 
and cancer-associated somatic mutations207. Whereas previous studies targeted specific loci in 
the genome, this study surveyed the entire genome. Soon this technology will enable the 
partitioning of single-cell genomes into microfluidic droplets for sequencing. Small but 
necessary advancements in single-cell partitioning and accurate long-read sequencing would 
enable fascinating studies into the evolution of single cells within an organism. 
Ideally, pairing these technologies would reveal the somatic mutation profile of each 
individual cell isolated from any biological sample (solid tumor, metastatic lesion, leukemia). 
With this information, it would be possible to reconstruct the exact phylogenetic tree in a single 
tumor and infer the step-by-step acquisition of mutations during the development of disease. This 
type of study will be possible with several key improvements to the current technology. First, the 
throughput of single-cell partitioning and genomic DNA isolation must be improved. While 
current reports have targeted a handful of loci in hundreds of cells, moving to whole genome 
sequencing for thousands of cells is a necessity. Second, allelic dropout during sample 
preparation is a key limitation of current single-cell sequencing platforms. Currently, this 
limitation is partially addressed by targeting many cells. Addressing these two limitation would 
permit several insightful studies into clonal evolution and the development of malignancy.  
Already, we understand that AML is an oligoclonal disease with multiple subclones often 
present at diagnosis62. Currently, MPFC enables the detection of these leukemic cells based on 
leukemia-specific cell surface markers that are not present on healthy cells92. The prevailing 
notion is that the founding AML mutations drive the leukemia-associated immunophenotype 
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(LAIP) and subclonal mutations do not alter that phenotype. This theory may need revision 
based on a couple of observations. First, LAIP almost universally changes between diagnosis and 
relapse for AML, even though relapse often arises directly from the founding clone64,102. 
Additionally, single-cell sequencing studies of ALL demonstrated that clonal heterogeneity for 
VDJ recombination at the immunoglobulin heavy chain (IgH) locus was linked to specific 
subclonal somatic mutations79. In one case, a subclone-specific EYA4 mutation allowed 
precursor B-cell populations to develop further resulting in VDJ recombination at the IgH locus, 
while other clones without the mutation were arrested in earlier stages of B-cell development. 
These B-cell maturation steps are tightly regulated and would result in subclone-specific 
immunophenotypes within the same tumor. The same process likely occurs in AML. Single-cell 
sequencing of AML samples could co-localize subclone-specific mutations and may predict 
immunophenotypic heterogeneity. A separate study could employ MPFC to partition various 
cellular compartments of an AML sample. Targeted ECS could then identify the subclonal 
mutations that govern each subclonal LAIP. These types of studies would further elucidate the 
clonal structure in AML. 
  Future advancements in single-cell and long-read sequencing could also dramatically 
improve residual disease detection in hematological malignancies. In the future, following 
treatment for AML, residual disease could be assessed with the following hypothetical protocol. 
The patient’s bone marrow is flow sorted to isolate individual HSCs and any persistent leukemic 
stem cells. Those sorted cells are partitioned into microfluidic chambers bound by a membrane 
studded with nanopores. Each cell is lysed and the entire genome is read, one chromosome at a 
time, through the nanopores. Bioinformatics analysis identifies the cell-specific somatic 
mutations and reconstructs the clonal architecture of the sample. The likelihood of relapse is 
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assessed based on the specific somatic mutations present and their clonal co-localization. If 
additional treatment is warranted, the specific somatic mutations present would inform 
therapeutic selection. While purely hypothetical, the tools will soon exist to make this type of 
personalized care a reality.  
The cytotoxic therapy given to eradicate a hematological malignancy wreaks havoc on 
the healthy hematological compartment. A robust single-cell sequencing approach would be able 
to examine the kinetics and genetics driving clonal expansion during recovery after 
chemotherapy exposure. Already, clonal expansion of nonleukemic clones has been observed 
following treatment for AML112. This phenomenon is probably closely related to the 
development of t-AML/t-MDS, which we already demonstrated can arise from pre-existing 
clones harboring TP53 mutations134. A sensitive single-cell sequencing approach could identify 
these clones before chemotherapy exposure, track them longitudinally, and identify the co-
operating mutations within a single cell that initiate leukemic transformation.  
5.8 Normal hematopoietic stem cell biology 
These techniques would also enhance our understanding of clonal hematopoiesis in 
healthy individuals. We have demonstrated that clonal expansion harboring leukemia-associated 
mutations are a common phenomenon in healthy elderly individuals. While we know these 
clones are pervasive, stable longitudinally and accumulate as a function of age, it is unknown 
what specific events are necessary to develop AML. While we identified many mutations per 
individual, we are unable to determine if they arise in the same HSPCs or occur in isolation. A 
whole genome single-cell sequencing approach could co-localize mutations. Expanding these 
techniques with longitudinal banking of pre-leukemic samples, would elucidate the stepwise 
process of mutation acquisition within single cells that drive leukemic transformation. This 
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information will be essential for developing a sequencing-based screening tool for hematological 
malignancy. Thoroughly understanding this phenomenon in liquid tumors may someday permit 
screening for nascent solid malignancies in cfDNA.  
One interesting observation made in our study of benign clonal hematopoiesis was that 
rare somatic mutations were not randomly distributed across the target space. We initially 
hypothesized that with a limit of detection of 0.0001 VAF and an estimated 10,000 HSCs in an 
adult, we would observe the private passenger mutations present in the specific HSCs 
contributing to hematopoiesis at the time. Instead we observed strong selection for mutations in 
the epigenetic modifiers DNMT3A and TET2. However, even in the first WGS study of a single 
case of AML, most of the somatic mutations identified were passenger mutations that reflected 
the life history of the initiating cell43. If single-cell sequencing can approach the accuracy of 
ECS, it would be possible to identify the progeny of each HSC based on their unique somatic 
mutation fingerprint. This would enable us to study the clonal dynamics of the hematopoietic 
compartment in healthy individuals. Currently, HSC dynamics are studied using viral barcoding, 
which perturbs the hematopoietic compartment and is confounded by the mutagenic effects of 
barcode insertion208,209. More recent approaches in mice have leveraged the Sleeping Beauty 
transposase to avoid transplantation to demonstrate that most blood production originates from 
long-lived progenitor cells, rather than HSCs210. Still, the mutagenic effect of random transposon 
insertion is unknown and none of these studies have examined native hematopoiesis in humans. 
All of these limitations could be addressed by a study using accurate single-cell whole-genome 
sequencing.  
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5.9 Targeting therapy in the AML genome 
Currently, treatment for AML (except acute promyelocytic leukemia) consists primarily 
of chemotherapy that targets rapidly dividing cells. The primary drugs used for induction therapy 
are cytarabine (a nucleoside analog) and an anthracycline drug (an intercalating agent). 
Following induction, consolidation therapy with cycles of high dose cytarabine attempts to 
eradicate persistent disease. Many of these patients will receive a stem cell transplant to replace 
their hematopoietic compartment with healthy hematopoietic stem cells from a donor or 
themselves. Regardless, many patients go on to relapse and the five-year survival for AML is 
26%211. Outcomes are particularly bleak in older individuals who cannot tolerate intensive 
chemotherapy or stem cell transplant, and most relapse within two years. The primary limitation 
of these treatments is that they do not target the leukemic cells directly, but rather all rapidly 
dividing cells.  
In contrast, targeted therapeutics interact with specific molecular targets that directly 
disrupt tumor growth. The most famous example, imatinib mesylate, directly targets the BCR-
ABL translocation, which is the initiating lesion in CML212. Unfortunately, there are currently 
few targeted therapeutics for treating AML, but many are currently in development213. 
Optimistically, in the future, AML may be treated as a chronic illness instead of a death 
sentence. At diagnosis, rapid, accurate sequencing of the tumor could inform selection of 
targeted therapeutics to eradicate the primary tumor and mitigate the clinical symptoms of 
disease. Following initial treatment, sensitive single-cell sequencing (described previously) could 
identify the persistent leukemic clones and their assortment of co-occurring somatic mutations. 
Here, multiple targeted therapeutics could target these specific residual clones. The process 
would be repeated months to years later to again selectively target and remove persistent disease. 
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This treatment approach has several key advantages over the current standard of care. First, 
therapy would not target healthy rapidly dividing cells, reducing the side effects of treatment. 
Second, targeted therapy would remove the severe selective pressure on the HSC compartment 
introduced by current chemotherapies that drive clonal expansion of pre-leukemic and non-
leukemic clones112,134. Third, a lower side effect profile would enable treatment in older 
individuals that cannot tolerate current induction therapy. Advancements in AML residual 
disease detection, prognostication and therapy will be applicable to other types of malignancy. 
Together, these advancements will empower future clinician scientists to personalize effective 
care for these devastating malignancies. 
5.10 Conclusion 
Upon reflection, it is humbling to realize the small contribution that all of this work has 
made to our understanding of leukemia and normal hematopoiesis. We developed novel methods 
that enhanced current sequencing technology to characterize previously undetectable rare clonal 
mutations. However, the technology is always improving. Soon the protocols developed here 
will be hopelessly outdated. I welcome that day and optimistically look forward to the 
technological advancements that will embellish and challenge our conception of biology, and 
improve the health and survival of our species.  
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